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Resumo 
 
A Salvia divinorum é presentemente considerada uma das drogas recreativas mais 
populares entre adolescentes, sendo legalmente comercializada em vários países e regiões, em 
“smart shops” e através da internet. Na presente pesquisa, o composto alucinogénio da droga, 
a salvinorina A, foi identificado e quantificado, juntamente com outras 3 salvinorinas (B, C, e 
D), com o intuito de verificar a informação fornecida aos consumidores em 10 produtos 
contendo extratos concentrados de salvinorina A, com potências rotuladas entre “5X” e “60X”. 
A extração com acetonitrilo revelou-se eficiente, e a análise foi realizada por cromatografia 
gasosa e espectrometria de massa. As concentrações de salvinorina A variaram entre 2,6 
µg/mg to 521,2 µg/mg, muitas vezes contrariando a informação adiantada pelos 
comerciantes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: Salvia divinorum, salvinorina A, extratos concentrados, Smart shops, drogas 
legais.  
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Abstract 
 
Nowadays, Salvia divinorum is considered one of the most popular recreational drugs 
among adolescents, being legally commercialized in many countries in “smart shops” and 
internet websites. In the present research, the hallucinogenic compound of the drug, salvinorin 
A, was identified and quantified, alongside with 3 other salvinorins (B, C and D), in order to 
verify the information provided to consumers in 10 products containing concentrated extracts 
of salvinorin A, with labeled potency between  “5X” and “60X”. The extraction was found to be 
efficient with acetonitrile, and the analysis was performed by gas chromatography mass 
spectrometry. The concentrations of salvinorin A ranged from 2,6 µg/mg to 521,2 µg/mg 
contradicting the information advanced by marketers. 
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1- Salvia divinorum and other natural products for recreational uses: brief overview  
 
Since synthetic drugs of abuse such as cocaine and amphetamine became scheduled 
under national and international drug laws, unregulated natural products have become more 
attractive for those who want to experience new psychotropic feelings and maximum 
enjoyment. 
In this context, the opportunity to legally sell psychoactive drugs, gave the opportunity 
to retail stores, known as “smart shops” or “head shops”, to increase their sales volume and 
capital gain. Also, the internet market for natural products intended to be used for 
recreational purposes has been an increasing reality (Arunotayanun & Gibbons, 2012). 
One of the most popular natural legal drugs, in many countries, is Salvia divinorum. 
According to Schmidt et al. (2011), in websites headquartered in United Kingdom (country with 
the largest percentage of online suppliers in Europe), Salvia (Salvia divinorum) ranks the top 5 
selling products alongside with Kratom (Mitragyna speciosa), Hawaiian Baby Woodrose seed 
(Argyreia nervosa), Fly agaric (Amanita muscarita) and Genie (chemically complex mixture of 
synthetic cannabinoids and plants). 
Data from EMCDDA (2011a) revealed that European stores selling Salvia divinorum 
have raised from 72 to 110, from January 2011 to July 2011. This represents an increase of 
approximately 53%, in only 6 months. According to the same source, the average price also 
helps to develop customer loyalty: on average, 10 g of Salvia divinorum costs between 6-12€. 
 
Besides the fact that natural products used as psychoactive drugs circumvent legal 
constraints, it is especially disturbing for scientific community the fact that these products do 
not provide information on eventual side effects, precautions, contraindications and most of 
the times, do not even provide reliable information on its qualitative and quantitative 
composition. This lack of information combined with the facility to buy these drugs and the 
similar psychoactive effects to those of synthetic ones, represents a threat, not only for users, 
but also for society in general. 
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2- The plant Salvia divinorum 
 
2.1 Historical Background  
 
The American continent is a geographic area known for its abundance in psychoactive 
mushrooms and plants. Actually, in America, it can be found many natural plants and 
mushrooms having hallucinogen properties, growing in forests, in fields, or in mountains.  
Archeological findings had proven the use of these mushrooms and plants over 5000 years in 
pre-Colombian period for magic and/or religious practices as well as for therapeutic purposes 
(Carod-Artal, 2011).   
Hallucinogen plants used by Mesoamerican populations are commonly referred as 
entheogens, because of its mysticism stimulation and divine communication. The main goal of 
practices in which these plants are used, is to reach a state of trance.  The altered state of 
consciousness level is characterized by time-space misdirection, inner peace sensation, 
hallucinations and a nature bond feeling. Mesoamerican religions recognize shaman as a 
person capable of maintain communication between physical and spiritual worlds, and the one 
who provide entheogens for religious ceremonies. The shaman uses several psychoactive 
substances for several purposes: contact with spirits, diagnose illnesses, insure good harvests 
or predict rain (Carod-Artal, 2011).  
In the Mazatec indigenous culture of Oaxaca (Fig.1), the plants with spiritual 
connotation, and historically the most important, are Salvia divinorum, the Teonanacatl (also 
called "magic mushroom"), and hallucinogenic morning glory, also known as Ololiuqui. The 
name “Salvia” comes from the Latin word that means "to heal” (Imanshahidi & Hosseinzadeh, 
2006). Salvia divinorum is a small perennial shrub specie of the mint family Labiatae, subgenus 
Calosphace, subgenera Salvia, native from the Northern Mexico, also known as “Maria 
Pastora”, “The Diviner’s Sage”, “Hierba Maria” and “eye of the shepherdess”, and has been 
used by Mazatec shamans in Oaxaca for over 3000 years (Turner, 2004). 
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Salvinorin A (Fig.2) is the main psychoactive compound present in Salvia divinorum. It 
is a kappa opioid receptor (KOR) agonist (Imanshahidi & Hosseinzadeh, 2006). The lethargy 
induced by this plant was mainly used for divination practices. Nevertheless, shamans also use 
Salvia divinorum for therapeutic purposes, like headache, abdominal pain and diarrhea (Carod-
Artal, 2011; Turner, 2004). Plant's leaves are usually ingested unchanged, or can be used to 
brew tea (Gonzalez et al., 2006; Halpern, 2004).  
 
 
 
 
 
 
 
 
 
 
 
Salvia divinorum was firstly described in western literature by the swedish 
anthropologist, Jean Basset Johnson, in 1939, who was particularly recognized by his previous 
studies on mushrooms used by earlier civilizations.  Salvia divinorum was a very rare plant, 
Fig. 1 - The Sierra Mazateca located within southern Mexico. Adapted from 
http://neighborsabroad.org/wphome/?page_id=76 
 
Fig. 2 - Salvinorin A Chemical Structure 
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which was difficult to find in its natural ecosystem, the Sierra Mazateca mountains. However, 
due to its easy propagation by cuttings, Salvia divinorum has been cultivated in botanical 
gardens and private collections, in several countries. As Cannabis, Salvia divinorum (Fig.3) can 
be grown indoors, or in any humid and semitropical environment (Hoover et al., 2008; Turner, 
2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The production of Salvia divinorum is inexpensive, being a great advantage for its 
intensive production. A small investment in fertilizers and solvents (for extraction of active 
compounds), combined with basic laboratory knowledge, makes the plant much more 
attractive to produce than its competitors, like Lysergic acid diethylamide (LSD) or 
phencyclidine derivatives (Valdes, 1994). It is believed that commercialized Salvia divinorum in 
circulation has been propagated from two parent clones of the species: one collected by R. 
Gordon Wasson in 1962, and the other collected by Bret Blosser, in 1991 (Turner, 2004). In 
fact, R. Gordon Wasson (ethnobotanist responsible for the revealing of the Mexican 
mushrooms to the modern world) and Albert Hofmann (renowned chemist involved in the 
discovery of LSD-25), were the first two persons to reap samples of Salvia divinorum and bring 
them to western civilizations, in 1962. In that year, both went to Oaxaca with the purpose of 
finding this mysterious plant used for religious and therapeutic purposes and carried the first 
specimens to United States of America (USA) (Halpern, 2004).  
Mazatec Indians believe that Salvia divinorum is not an autoctone plant of this region. 
Actually, the few patches of known existence in Sierra Mazateca seem to be the result of 
Fig. 3 - Salvia divinorum plant. From http://psychotropicon.info/salvia-
divinorum-diviners-sage-ska-maria-pastora/ 
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deliberate planting and anthropological distribution. It is possible that Salvia divinorum is a 
hybrid, however, there are no proven theories about its eventual prospective parents (Jenks. 
et al., 2011). It has been noticed that, among Mazatec Indians, the plant does not have an 
indigenous name. It is called “Diviner’s Sage” or by other designations related to Christian 
customs like “the shepherdess” or “Mary”. This may be explained by the birth or recognition of 
the plant, only after the decline of the Aztec Empire in the battles against the Spanish Army 
conducted by Hernán Cortés, in 1520. However, Gordon Wasson suggests another possibility: 
Salvia divinorum might also be the Aztec plant Pipiltzintzintli, an entheogen with very little 
available information, and supposed to be extinguished (Turner, 2004).  
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2.2 Phylogenetic Classification 
 
Salvia divinorum has been phylogenetically classified in the family Labiatae, subgenus 
Calosphace, subgenera Salvia. Nevertheless, the phylogenetic classification of Salvia divinorum 
remains controversial. 
There have been advances and retreats on the similarity of the specie Salvia divinorum 
to other plants classified in taxonomic sections Dusenostachys or Tubiflorae, even using 
different approaches, like molecular phylogenetics, floral morphology or any other (Epling & 
Játiva-M, 1962; Jenks, 2009) (Fig.4). Making use of recent technologies, studies involving DNA 
from chloroplasts and the entire nuclear ribosomal internal transcribed spacer region to 
determine phylogenetics tree, it was discarded the possibility to include Salvia divinorum in 
Dusenostachys section. In fact, in accordance with the mentioned tests, only S. venulosa 
species seems to be similar to Salvia divinorum among all the species of the Calosphace 
subgenus. S. venulosa is classified among other plants in the Tubiflorae section. Hence, 
according to Jenks. et al. (2011), Salvia divinorum should no longer be classified within 
Dusenostachys, and should be classified in a phylogenetic position nearest to S. venulosa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 4 - Phylogeny of Salvia divinorum. from Jenks A, Walker J, Kim S. Evolution and origins of the Mazatec hallucinogenic sage, Salvia 
divinorum (Lamiaceae): a molecular phylogenetic approach. Journal of Plant Research. 2011;124:593-600 
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2.3 Prevalence, Patterns of use and legal status 
 
The prevalence of Salvia divinorum use at a global scale is, for the moment, unknown. 
Nevertheless, it seems particularly prevalent in Northern American countries, namely USA and 
Canada. Ford et al. (2011) estimated that 1.7% of adolescents from USA aged 12-17, used the 
substance until 2008–09, whereas, in Canada, the prevalence, in the same period, reached 
6.2% (Currie, 2013).  
Salvia divinorum was traditionally used by Mazatec Indians in Oaxaca for more than 
3000 years for medical purposes (Valdes et al., 1983).  However, in the late 1990s, the use of 
Salvia divinorum became more associated with recreational practices, rather than spiritual or 
therapeutic. Unlike those times, nowadays, the plant is not mainly chewed or ingested, but it is 
more often smoked in pipes, similarly to those commonly used with Cannabis. With this 
different administration route, the effects have also changed. When smoked, Salvia divinorum 
expresses its effects immediately and yields a dissociative sensation (Gonzalez et al., 2006; 
Stogner et al., 2012). Highly concentrated liquid extracts (like tinctures) are also available in 
different websites, as well as the leaves for chewing (Hoover et al., 2008).  
Due to the worldwide globalized culture, the plant used in a restrict region of Oaxaca 
became quickly used at different places of the globe. Some studies have focused on the 
importance of the videos broadcasted in websites like YouTubeTM , showing moments lived by 
anonymous people, after Salvia divinorum consumption (Halpern, 2004; Schmidt et al., 2011; 
Vohra et al., 2011). Also, in sites designed to divulgate and sell legal drugs, Salvia divinorum is 
one of the most widespread, followed by Kratom and some mushrooms (Gonzalez et al., 2006; 
Schmidt et al., 2011).  Most Salvia divinorum consumers confirmed they first heard about the 
plant through friends, and only 40% admitted to have purchased the product themselves (Ford 
et al., 2011). Salvia divinorum is most commonly acquired in the Internet, in “smart shops” 
(also known as “head shops”), in music festivals or through drug dealers (Gonzalez et al., 2006; 
Schmidt et al., 2011; Vohra et al., 2011). Websites that promote Salvia divinorum usually attest 
the drug's safety, absence of adverse effects and mistaken effects of euphoria and analgesia 
(Hoover et al., 2008).  
Ilgen et al. (2011) conducted a study in USA named "Monitoring the Future", that 
revealed the use of Salvia divinorum among teenager students, between 1987 and 2008. The 
study found out that 5.5% of the 12th graders, 3.7% of the 10th graders and 1.7% of the 8th 
graders, have already tried Salvia divinorum. In 2008, The National Survey on Drug Use and 
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Health claimed that 0.6% of the adolescents (aged 12-17) and 1.7% of young adults (aged 18-
25) had used Salvia divinorum in the previous year (Ford et al., 2011). Among other similar 
studies, these results reveal the high prevalence among young adults. In summary, the 
prevalence studies that have been made reveal a high prevalence among young male adults, 
living on-campus, fraternity members, which are engaged in risk-taking behaviors (like selling 
illicit drugs and stealing), and that consume other drugs, especially cannabis.  In fact, polydrug 
use is the most robust determinant of S. divinorum consumption. The percentages above cited 
indicate a similar and sometimes higher adhesion to Salvia divinorum than to LSD, ketamine, 
phencyclidine or dimethyltryptamine (Lange et al., 2008; Perron et al., 2012; Stogner et al., 
2012; Wu et al., 2011). 
Consumers of Salvia divinorum, using it as a recreational drug, face the same risks as 
users of other recreational drugs: possible future drug addiction, accidents caused by mental 
impairment, overdoses linked to inexperience drug intake and the long run effects of 
prolonged drug abuse (Pavarin, 2006). 
 
 
Salvia divinorum became legally controlled, in 2003 by a municipal law in Saint Peters, 
Missouri, USA, that restricted Salvia sales.  In August of 2005, Louisiana approved a law to 
implement the suppression of production, manufacture and distribution of Salvia divinorum, 
as well as other forty plants.  Missouri, Maine, Tennessee, North Carolina, West Virginia, 
Wisconsin, Delaware, Oklahoma, North Dakota, Florida, Illinois, Kansas, Mississippi, Virginia, 
Hawaii, Nebraska, Ohio, South Dakota, Alabama, Georgia, Kentucky, Michigan, Minnesota, 
Connecticut, Indiana, Pennsylvania, Wyoming and Colorado are the other states that predict 
punishment for the use and/or production of Salvia divinorum, or its main compound 
salvinorin A (Stogner et al., 2012). The U.S. Drug Enforcement Administration has identified 
Salvia divinorum as a "drug of concern" since 2005, although, under U.S. federal law, it is not 
illegal to possess the drug. Countries such as Australia, Belgium, Denmark, Italy, Japan, Latvia, 
Lithuania, Romania, Sweden and some states of the US, included Salvia divinorum and 
salvinorin A in drugs legislation. Croatia, Germany, Poland and Spain only regulate the plant 
whereas in Estonia, Finland and Norway, Salvia divinorum is included in medicines legislation. 
In Canada it is legal to sell Salvia divinorum but only upon authorization under the Natural 
Health Products Regulation(EMCDDA, 2011b) (Fig.5).  
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Sumnall et al. (2011) performed a study in United Kingdom in which 154 recent users 
of Salvia divinorum were surveyed. About one quarter of participants reported that they 
started consuming Salvia divinorum as an alternative to illegal drugs. Nevertheless, the 
majority of the participants reported that they would continue to use the plant, even if it was 
illegal. The authors assumed that these data might be related to the fact that consumers 
attribute lower toxic effects to Salvia divinorum than to other similar drugs. It was concluded 
by these authors that legal controls would have no impact to dissuade former users to 
purchase the drug. Nevertheless, although the drug did not come to be eradicated, the fact of 
becoming socially less acceptable could have long term effects on consumption and sale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Portugal, consumption and marketing Salvia divinorum had no restrictions, since its 
main compound (salvinorin A) was not included in national Decree Law 15/93 (DL15/93), that 
identifies legal status of trafficking and consumption of narcotic and psychotropic drugs 
(INFARMED, 1993).  Nevertheless, in 17th April 2013, it was published the Decree Law 54/2013  
that defined the prohibition over advertising, trading, production, importation, exportation, 
distribution, sale or possession of the new psychoactive substances. Salvia divinorum is one of 
the mentioned “new psychoactive substances” alongside with other plants such as Mitragyna 
Speciosa, Amanita muscaria, Piper methysticum, Areca catechu and Kava. Phenylethylamines, 
piperazines, cathinone derivatives, synthetic cannabinoids and analogs of cocaine were also 
targeted in the Decree Law 54/2013 (República, 2013).  
Fig. 5 - Countries with legal implications regarding Salvia divinorum until 2012 
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2.4 Other compounds identified in Salvia divinorum plant  
 
Salvinorin A might be considered the most important active compound present in 
Salvia divinorum. Although this plant has other recognized chemical compounds, salvinorin A is 
present in much higher concentrations than the remaining compounds, which may be 
insignificant from the pharmacological point of view (Listos et al., 2011).  
After the identification of salvinorin A and B, many other diterpenes were isolated 
from Salvia divinorum samples: salvinorin C (with weak affinity for KOR and none psychotropic 
effects in humans) (Valdes et al., 2001); salvinorins D-F (salvinorins D and E are believed to be  
precursors of salvinorin A) (Munro & Rizzacasa, 2003); salvinorin G (Lee et al., 2005); 
salvinorins H-I (Shirota et al., 2006); salvinorin J - biosynthetically, salvinorin J is probably 
derived from salvinorin I by an acetyltransferase action and might represent a key 
intermediate in a novel biosynthesis pathway of salvinorin A, via salvinorin I (Kutrzeba et al., 
2010); divinatorins A-C (Bigham et al., 2003; Shirota et al., 2006); divinatorins D-E (Lee et al., 
2005); salvinicin A and B (salvinicin B is mentioned as the first µ-opioid  antagonist having a 
neo-clerodane skeleton) (Harding et al., 2005); and salvidivins A-D (Shirota et al., 2006) (Fig. 6). 
Among all chemical compounds mentioned, only salvinorin G, salvinicin A and divinatorin D 
had measurable affinities for KOR (Harding et al., 2005; Lee et al., 2005). Salvinorin A remains 
the only isolated neoclerodane diterpene linked to high affinity for KOR. 
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Salvidivin D 
Fig. 6 - Chemical structures of the compounds already identified in 
Salvia divinorum plant 
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2.5 - Routes of Exposure 
 
The traditional consumption of Salvia divinorum involved chewing the plant or brewing 
it as an infusion. Nowadays, it is used as a recreational drug, hence, the extract of the leaves is 
more often smoked (Siebert, 1994; Singh, 2007).  
Siebert (1994) compared the effects of inhaled Salvia divinorum vapors, absorption of 
an alcohol-based spray of Salvia divinorum and the ingestion of capsules with the same 
quantity of plant. Inhalation of 200 µg as a vapor was the most efficient method. Through this 
administration route, the effects started to be expressed at the end of 30 seconds. The 
absorption of the spray, proved to be active, but only a small percentage of salvinorin A was 
absorbed. In this case, the compound also took about 30 seconds yielding psychoactivity. No 
psychoactivity was found following ingestion of the capsules with salvinorin A.  The maximum 
dose administered by inhalation was 2600 µg. No acute or long-term negative effects were 
reported (Siebert, 1994). As later evidenced by Mendelson et al. (2011), the oral absorption of 
Salvia divinorum active compounds was very unlikely and irrelevant. No psychoactive effects 
were obtained in either studies of Siebert (1994) and Mendelson et al. (2011) by oral 
administration of Salvia divinorum, presumably due to the unreliable sublingual absorption of 
the plant’s active compounds. In the study of Mendelson et al. (2011), performed with 8 adult 
subjects, 7 different doses were sublingual administered to each person, ranging from 0 to 
4000 µg of salvinorin A, being the administrations separated by at least 24h. Even the higher 
concentration did not even produced mild effects. The different results obtained, collected 
through questionnaires between the experimental group (who had taken Salvinorin A) and the 
placebo group, were not statistically significant. When taken orally, salvinorin A seems to be 
degraded in the gastrointestinal tract and, as aforementioned, only a small dose of the drug 
suffers sublingual absorption. These data might explain the fact that, in traditional use, Salvia 
divinorum produces only mild effects whereas, through the most recent practices, the 
reported effects are much more intense (Imanshahidi & Hosseinzadeh, 2006).  
A recent study performed by Addy (2012) confirmed the extension of self-reported 
effects in humans who had smoked Salvia divinorum. In this work, 32 volunteers smoked 25mg 
of plant material, using a smoking pipe. It was registered the blood pressure, heart rate, 
temperature and respiration rate. The effects produced by the drug were also evaluated 
through self-reported effects and observer-rated effects [1]. Observer-rated effects such as 
laugh and hyper movement were reported after the subjects smoke an active dose of 
[1] Observer-rated behavior studies – Studies in which the subjects behavior is evaluated and classified, by a specialist, after some kind of 
stimulation (chemical, physical, environmental, or any other). 
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salvinorin A, however, no changes in blood pressure, heart rate, temperature or respiration 
rate occurred. Even knowing that a small dose of smoked salvinorin A is enough to produce 
several of the drug’s effects, it should be taken into account that there are variations in 
smoking techniques and the instruments used may interfere with combustion of the drug, 
varying the dose administered. Therefore, the attribution of a minimum dose value to elicit 
psychoactivity, should be made carefully (Mendelson et al., 2011). 
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[2] Forced Swimming Test –In this test the animal is submitted to trials in which he tries to escape from an acrylic glass cylinder filled with water. 
The time that the animal spends without moving is supposed to be decreased by antidepressants.    
2.6 Salvia divinorum psychoactive effects 
 
2.6.1 – Effects on animal models 
 
Some experiments, namely the forced swimming test[2] with rodents (rats and mice), 
revealed decrease of mobility after administration of Salvia divinorum, thus contradicting the 
effects reported by Lange et al. (2010)  in humans, mentioned earlier (John et al., 2006). These 
results might be related to the fact that high doses were used in these cases. In fact, small 
doses seem to promote the hyper-movement (acting as stimulants and increasing dopamine 
levels), while high doses seem to promote hypo-movement (acting as depressing and 
diminishing dopamine levels) (Baker et al., 2009; Braida et al., 2007; Carlezon et al., 2006).  
In contrast to other drugs, Salvia divinorum has a low addictive liability, being unlikely 
to be used compulsively, repetitively, or persistently. This might be related to the fact that 
addictive drugs usually increase dopamine in the nucleus accumbens, contrary to what seems 
to happen with Salvia divinorum. According to studies in rodents, Salvia divinorum decreases 
dopamine levels (likely to what has been demonstrated with other KOR agonists) (John et al., 
2006; Willmore-Fordham et al., 2007; Zhang et al., 2005). These results encourage the possible 
benefit of use Salvia divinorum to treat drug dependence (for instance, with cocaine), mainly 
due to the effects of salvinorin A on dopamine-mediated receptors (Johnson et al., 2011; 
Morani et al., 2009). 
In studies performed with mice, salvinorin A caused antinociception in tail flick[3], hot 
plate[4] and acetic acid[5], reinforcing the potential analgesic effect of Salvia’s most active 
compound (Ansonoff et al., 2006; John et al., 2006). 
 
2.6.2 – Effects reported in humans 
 
Most information concerning psychoactive effects of Salvia divinorum are obtained 
from questionnaires and the answers frequently extol the “intense” and “unique” effects of 
the drug (Lange et al., 2010; MacLean et al., 2013) ranging the required dose to produce 
hallucinogenic effects from 200 µg to 600 µg of salvinorin A (Siebert, 1994).  
  
[3] Tail Flick Test – Evaluation of the nociceptive response latency in rats, with recording of time between the time when a light beam is focused 
on its still tail, and the time that it begins to move. 
[4] Hot Plate Test - Evaluation of the nociceptive response latency to hind paw licking in mice, when these are placed on a heated metal plate. 
[5] The acetic acid induced writhing – Evaluation of the response to mediate peripheral pain, induced by peritoneal injection of acetic acid, from 
abdominal contractions in mice. 
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The fast onset of Salvia divinorum’s effects is remarkable, being noted in seconds or 
few minutes (Baggott et al., 2010; Ranganathan et al., 2012). 
Gonzalez et al. (2006) reported a questionnaire about the psychoactive experience 
lived during the consumption of this drug, translated into 75% of the responses between 
"intense" to "very intense" and "very intense" to "extremely intense". The answer "moderate" 
collected 19% of the responses, while the word "light" was chosen only in 6% of cases. The 
positive effects more commonly cited were the trip (41%), followed by euphoria (28%) and 
dissociative effects (19%). The negative effect more frequently mentioned was the short 
duration (38%). The results reflect the main goals of this drug consumption as well as the 
expectations of its consumers. 
Salvia divinorum induces significant alterations in behavior and cognition. Some effects 
of Salvia divinorum are consistent, in different studies, such as “hyper-movement”, “emotional 
effects” (especially fear), “speech effects” and “heating effects” (the users revealed feeling of 
increasing temperature during the experiment) (Addy, 2012; Johnson et al., 2011). However, 
although Salvia users’ respondents assumed to feel high temperature during the experiment, 
recorded rectal temperature decreased in some studies (Ansonoff et al., 2006).  
Short-lasting depersonalization, visual and hearing hallucinogenic effects (sense of 
becoming objects, visions of two-dimensional surfaces,  motion sensations and overlapping 
realities, perceptual distortions and profoundly altered sense of self and environment) are 
quite marked, and users classify them as unique and substantially different from other 
hallucinogens (Baggott et al., 2010; MacLean et al., 2013). The dissociative effects are evident 
for moderate and high doses (MacLean et al., 2013; Ranganathan et al., 2012). Some other 
described effects of Salvia divinorum consisting on hysterical laughter and feelings of 
transformation into people or animal, being in multiple places at the same time and even 
levitation (Singh, 2007).  
It was found an inverse correlation between the dose and recognition accuracy. The 
follow up after the screening has not shown any signs of depressive effects, anxiety, confusion, 
psychiatric symptoms or visual disturbances (MacLean et al., 2013). These results corroborate 
those obtained by Gonzalez et al. (2006), where users usually claim positive after-effects, such 
as increased insight and improved mood. A study performed by Baggott et al. (2010) revealed 
that more than 24h after Salvia divinorum consumption, 25.8% of the participants reported 
positive effects and 46.5% reported improved mood. Regarding to the most persisting effects 
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over a shorter time frame, 44.8% of the individuals reported improved mood and 42.6% 
reported a feeling of calmness. 
In another study, in which individuals were monitored, no serious adverse effects 
(death, hospital stay or emergency room visit) occurred; being drowsiness and dizziness the 
only adverse effects registered (Baggott et al., 2010). The first reported case of a persistent 
negative outcome related to the use of Salvia divinorum was related in 2009. A 21 years old 
person evidenced persistent psychosis and paranoia after smoking Salvia divinorum. 
Nevertheless, the medical team suspected that the patient was genetically predisposed to 
schizophrenia, and Salvia might have precipitated the clinical manifestations (Przekop & Lee, 
2009). The “loss of awareness” that might result in users hurting themselves or others 
(Killinger et al., 2010), is another consequence linked to Salvia divinorum consumption. 
Although, there have been only few documented negative occurrences associated with Salvia 
use and the eventual long-term dependence seem to be unlikely, the coordination loss, failure 
on speech, interpersonal impairments and loss of self-care should be valued as an increased 
risk to users and those around them (risks of injury, interpersonal conflict and property 
damage)(Lange et al., 2010).  
Nevertheless, there is little data on human experimentation with Salvia divinorum, and 
works presented in literature indicate different routes of administration, different doses, and 
lack characterization of the subject samples (Ranganathan et al., 2012).  
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3- The hallucinogenic compound Salvinorin A 
3.1. Physicochemical properties 
 
Salvinorin A was isolated for the first time by Ortega et al. (1982), and chemically 
characterized by nuclear magnetic resonance and single-crystal X-ray analysis. It was 
considered to be psychoactive for the first time in the 1990s (Valdes, 1994). The relationship 
between salvinorin A and the kappa opiate receptor was firstly established in 2002 (Roth et al., 
2002).  
 
Salvinorin A remains the most potent naturally occurring hallucinogen, being 
chemically and structurally unique: it is the first known psychoactive diterpene and the first 
non-nitrogenous hallucinogen (Killinger et al., 2010).  
Salvinorin A is chemically named as (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(3-
furanyl)dodechydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic acid 
methyl ester, and has the empirical formula C23H28O8 (Fig. 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The molecular weight of salvinorin A is 432.46 g/mol. Regarding physical data, the 
melting point of salvinorin A lies between 238-244 °C and the boiling point is 760.2 °C. 
Salvinorin A is thermo unstable, so it must be stored at -20 °C. 
Fig. 7 - Salvinorin A 3D Chemical Structure. From 
http://commons.wikimedia.org/wiki/File:Salvinorin_A-sticks.png 
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Salvinorin A is unstable in basic solutions and has a high solubility in organic solvents, 
such as acetone, chloroform, acetonitrile and methanol. It is however insoluble in hexane and 
water.  
Many attempts have been made to characterize Salvia divinorum through the 
detection of its most important compound, Salvinorin A. The UV spectrum of a methanolic 
solution of salvinorin A exhibits a peak at 211 nm. The characteristic m/z ions of salvinorin A 
are m/z 94, m/z 55, m/z 121, m/z 107, m/z 273, m/z 166, m/z 220, m/z 252, m/z 234, m/z 359, 
m/z 318, m/z 404 and m/z 432 (in decreasing abundance) (EMCDDA, 2011b; Sigma-Aldrich, 
2011). 
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3.2 Pharmacokinetics and pharmacodynamics of salvinorin A 
 
In vivo data, using humans and animal models, and in vitro methods have been crucial 
for the determination of the pharmacokinetics and pharmacodynamics of Salvia divinorum and 
its major constituent salvinorin A, as well as to elucidate its pharmacologic and toxicological 
effects. Nevertheless, these works are yet very scarce and further information is needed to 
elucidate the biological mechanisms involved. 
 
3.2.1.1 – Studies in animal models 
 
Teksin et al. (2009) demonstrated that, after administration, salvinorin A is absorbed in 
the lungs, reaches the systemic circulation, crosses the blood brain barrier and accumulates in 
the central nervous system. The pharmacokinetic study was performed in male Sprague-
Dawley rats. The animals were submitted to a single administration of 10mg/kg, and after 
euthanized, blood samples were collected and brain tissue was analyzed.  Salvinorin A can 
easily cross the blood barrier due to its low molecular weight (432.36 g/mol) and high 
lipophilicity. 
Positron emission tomography (PET) studies developed in baboons by labeling 
salvinorin A with carbon-11 revealed that salvinorin A easily crosses the brain blood barrier, 
taking only 40 seconds to reach 3.3% of the injected dose. After the baboons were 
anesthetized with intramuscular ketamine hydrochloride, a dose of 250mg of salvinorin A was 
administered through a catheter placed in a radial arm vein. It was demonstrated that the 
compound was distributed throughout the brain, with a high concentration in the cerebellum 
and cortex. High concentration of the hallucinogenic drug in cerebellum and visual cortex, 
might justify the behavioral effects portrayed when the drug is inhaled. The referred PET 
studies also estimated that less than 10 µg of salvinorin A in the human brain could be enough 
to promote its psychoactive effects, since in previous studies of Siebert (1994) it was shown 
that 200 µg of smoked salvinorin A was enough to promote the referred effects, and the 
maximum average brain concentration of salvinorin A corresponded to 3,3% of the 
administered dose  (Hooker et al., 2008).  
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3.2.1.2 – Studies in humans 
 
In a study performed by Gonzalez et al. (2006) with 32 recreational users of Salvia 
divinorum, 31% of the surveyed, have considered the onset of effects “instantaneous” and, 
57% considered it “less than a minute”. These answers were obtained through a retrospective 
assessment about the most recent Salvia divinorum consumption, and all the subjects revealed 
to have experienced psychotropic effects.  
 
3.2.2 – Metabolism and Excretion 
 
 
 
Fig. 8 - Hydrolysis of Salvinorin A into Salvinorin B 
 
 
 
3.2.2.1 – Studies in vitro 
 
Tsujikawa et al. (2009), have shown that 24h after administration in rats plasma, 
salvinorin A concentration decreased while salvinorin B concentration increased. Fresh whole 
blood was collected from anaesthetized male Wistar rats, plasma was separated by 
centrifugation and it was added 20µl of a salvinorin A solution. It is important to refer that the 
sum of the residual percentages of salvinorin A and salvinorin B did not attain 100%. These 
findings suggested that subsequent salvinorin B degradation occurred and/or there were other 
metabolic pathways of salvinorin A. Further analyses enabled to recognize a lactone-ring open 
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form of salvinorin B as its presumptive metabolite. In the same work, and in order to discover 
which esterase was responsible for salvinorin A degradation, various esterase inhibitors were 
experimented. The data obtained suggested that carboxylesterase would be the main 
responsible for that transformation since bis-p-nitrophenylphosphate (a carboxylesterase 
inhibitor) inhibited its hydrolytic activity (Fig. 8).   
Studies developed by Schmidt et al. (2005) in fresh whole blood taken from adults 
rhesus monkeys, showed that salvinorin B is the most representative metabolite of salvinorin 
A, resulting from the ester hydrolysis at the 2-acetoxy group by an esterase in blood. It was 
found an inversely proportional relationship between the concentrations for salvinorin A and 
salvinorin B (Fig.8). 
Teksin et al. (2009) demonstrated that salvinorin A is a substrate to the glycoprotein P. 
To enable the in vitro study of the glycoprotein P influence on salvinorin A efflux, MDCK-MDR1 
cell line was used as model since it encodes high levels of glycoprotein P. High secretory 
transport of salvinorin A of 4.07 ± 1.34 x 10-5 cm/s was observed. It is, however, important to 
relate these results with the behavior in vivo. Salvinorin A has, as already mentioned, high 
lipophilicity, potency and easy permeability over barriers, which probably outweigh the effect 
of P-gp-mediated efflux on the central nervous system levels.  
In vitro concentrations of salvinorin A significantly decreased after being exposed to 
the presence of the enzymes CYP2D6, CYP1A1, CYP2C18 and CYP2E1. These findings support 
the fact that salvinorin A is a substrate of CYP450. Glucuronosyltransferases enzymes, like 
UGT2B7, also seemed to diminish salvinorin A’s concentration, which might be associated to 
the ester group of salvinorin A, a potential site for glucuronidation, by those enzymes (Teksin 
et al., 2009).  
 
3.2.2.2 – Studies in vivo 
 
Salvinorin A, in rhesus monkeys studies, has been estimated to have an elimination t ½ 
of 56.6 ± 24.8 min, after intravenous administration (Schmidt et al., 2005). This fast elimination 
time, suggests a likely hysteresis and a consequent single-dose tolerance to the drug. Other 
studies performed with baboons showed an even faster elimination: half-time estimated of 8 
min, also after intravenous administration (Hooker et al., 2008). If the drug is so quickly 
eliminated, it is easy to understand why smoking is the preferred route of administration 
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nowadays: fast absorption and easy re-administration. This profile corresponds to the 
expectations of most of Salvia divinorum consumers (Baggott et al., 2010).  
It was tested the metabolism comparison among salvinorin A, salvinorin B, and 
salvinorin B ethoxymethyl ether (EOM-SB), a derivative with greater potency and resistance to 
metabolism in baboon brain. In order to perform this study, two male Sprague-Dawley rats 
were anaesthetized and injected with a solution with salvinorin A in the peritoneum. After 
that, PET imaging was performed. It would be expected that EOM-SB exhibit slow uptake and 
clearance in brain, since it was seen as the most resistant to metabolism, especially when 
compared with salvinorin A. Nevertheless, the three compounds revealed very similar 
pharmacokinetics in brain, concerning uptake and clearance. The obtained results showed that 
metabolism is not the only responsible for the brief brain residence of salvinorin A. On the 
other hand, whole-brain EOM-SB concentrations diminished more slowly than the 
concentration of the other two compounds after intraperitoneal administration (Hooker et al., 
2009). 
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3.3 Physiological and toxicological properties of salvinorin A 
 
Despite the fact that all plants of the genus Salvia ssp. possess a wide range of 
pharmacological activities, such as sedative, hypnotic, muscle relaxant, analgesic, 
anticonvulsant and neuroprotective, Salvia divinorum has been the only species that exert 
hallucinogenetic activities, since it is the only one containing salvinorin A (Grundmann et al., 
2007). Salvinorin A has a psychotropic activity in humans at low doses ranging between 200 
and 500 µg, when vaporized and inhaled, making it the most potent compound occurring in a 
hallucinogenic plant (Siebert, 1994).  
Salvinorin A is a neoclerodane diterpenoid which acts as a kappa opioid receptor 
agonist (Lovell et al., 2012; Roth et al., 2002). This fact made clear that its mechanism of action 
is different from the other hallucinogenic drugs. It was proven that salvinorin A is efficient in 
particular transduction systems and has a reduced propensity to cause receptor 
desensitization (Roth et al., 2002).  
It has also been restated the absence of a basic nitrogen in the chemical structure of 
salvinorin A (Fig. 8), believed to be crucial in traditional opioid pharmacology, as reported for 
morphine, codeine and heroine molecules (Fig.9) (Lovell et al., 2012; Vortherms & Roth, 2006). 
Therefore, salvinorin A represents the first non-alkaloid opioid receptor type-selective drug 
(Lee et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
Salvinorin A has a high selectivity for kappa opioid receptors, having no activity in most 
of other systems, such as serotonergic, or in N-Metil-D-Aspartate receptors (Butelman et al., 
A B C 
Fig. 9 - Codein (A) , heroin (B)  and morphine (C) chemical structure evidencing the 
presence of Nitrogen (blue colored) 
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2004; Butelman et al., 2007). Data about structure/activity relationship, suggested that it is the 
carbon in the 2-position the main critical site for kappa opioid receptor binding and activation 
(Prisinzano, 2005).  
 
3.3.1 – Studies in cell lines 
 
Chavkin et al. (2004) compared the agonist activity of Salvia divinorum with dynorphin 
A, an endogenous neurotransmitter of the kappa opioid receptor, by measuring potassium 
conductance through G protein-gated K+ channels in human embryonic kidney cells and 
oocytes. The results obtained suggest that salvinorin A was equieffective and equipotent to 
dynorphin A. In the same research, salvinorin A expressed itself as more potent than 
dynorphin A and have higher efficacy than U50.488 and U69.593.  
Some in vitro studies have shown that salvinorin A does not interact with 
endocannabinoid system. Salvinorin A has no influence on calcium ion flux in hCB1 receptors, 
and did not displaced a radiolabeled CB1 receptor agonist ([
3H]-CP55,940) or a CB1 receptor 
antagonist ([3H]-SR141716), from hCB1 receptors expressed in chinese hamster ovary cells. In 
this work it was hypothesized that salvinorin A does not act directly on cannabinoid receptors, 
but could act by indirect pathways (Walentiny et al., 2010).  
 
3.3.2 – Studies in animal models 
 
Roth et al. (2002) demonstrated, by the first time, the interaction between salvinorin A 
and kappa opioid receptors. These authors measured the inhibition of forskolin-stimulated 
cyclic adenosine monophosphate (cAMP) in presence of salvinorin A and the intracellular Ca2+ 
mobilization in kappa opioid receptors expressed in guinea pig brain. 
Other studies also suggested that the mechanisms underlying salvinorin A 
psychoactive effects are quite different from serotonergic or glutamatergic hallucinogens, 
since salvinorin A failed to substitute other drugs like LSD or ketamine in Sprague-Dawley rats 
(Killinger et al., 2010). Nevertheless, the range of effects produced by salvinorin A has been 
considered similar to those produced by LSD, the main difference being the extremely short 
duration (Gonzalez et al., 2006; Listos et al., 2011).  Corroborating those findings, other studies 
performed with rhesus monkeys, also showed that salvinorin A was antagonized by nalmefene 
(a µ and kappa receptor antagonist), since sedation and postural effects, evoked by salvinorin 
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A administration, were prevented by nalmefene IV injection (0.1 mg/Kg). However, ketanserin, 
a selective 5-HT2 antagonist, failed to prevent the same sedation and postural effects. Classical 
psychedelics, like the already mentioned LSD, exert effects on the 5-HT2A serotonin receptor 
(Butelman et al., 2009).  
The evidence of salvinorin A being a kappa receptor agonist has been reinforced in 
studies with several animal models (like zebrafish, rhesus monkeys and rodents) trained to 
discriminate potent kappa agonists, such as U50.488 and U69.593 (Baker et al., 2009; 
Willmore-Fordham et al., 2007). Moreover, the effects produced by salvinorin A became 
attenuated after administration of nor-binaltorphimine (nor-BNI) and quadazocine, kappa 
opioid antagonists, to rats (Willmore-Fordham et al., 2007) and rhesus monkeys (Butelman et 
al., 2004), respectively.  The stimulation of kappa opioid receptors in brain (especially in 
cerebellum) and spinal cord by salvinorin A, also justifies its ability to induce antinociception in 
mice, measured by using the tail-flick test (Grundmann et al., 2007; John et al., 2006).  
While most kappa opioid agonists produce conditioned place aversion and decrease in 
locomotor activity, experiments with salvinorin A revealed an induction of conditioned place 
preference[6] and increase the spontaneous locomotor activity[7] of rodents, which allow to 
underline the possibility of other mechanisms be involved in the pharmacological effects of 
salvinorin A (Listos et al., 2011). It is hypothesized a new mechanism of action of binding and 
activation, not involving ionic interactions but hydrophobic interactions. The lack of strong 
ionic links and the existence of multiplicity of lipophilic binding sites, in the kappa opioid 
receptors, suggest that salvinorin A probably does not follow only one model (Grundmann et 
al., 2007). 
Salvinorin A has shown to modify dopaminergic pathways, namely decreasing 
dopamine levels in the caudate putamen and decreasing dopamine neurotransmission levels in 
the dorsal striatum, mostly by affecting dopamine release but not dopamine uptake. The 
intrastriatal administration of salvinorin A results in decreased dopamine levels in rats dorsal 
striatum, which is due to the activation of kappa opioid receptors, since pretreatment with 
selective kappa opioid antagonists, like nor-BNI, attenuated the evoked decrease in dopamine 
overflow (Braida et al., 2008; Gehrke et al., 2008; Listos et al., 2011). Similar results were 
obtained by Gehrke et al. (2008). 
It has also been proven that salvinorin A has affinity for dopamine D2 receptors, since 
its intraperitoneal administration in mice, decreased dopamine levels in caudate putamen. 
Nor-BNI blocked the effect of salvinorin A on dopamine levels of mice, corroborating the idea 
[6] Conditioned Place Preference Test – Condition used to study the rewarding and aversive effects of drugs. The animal might choose to 
move to one of two different apparatus, having in one of them the administered stimuli, and in the other the vehicle. The time the animal 
spends in any of the apparatus is measured to evaluate if a conditioned place preference was found. 
[7] Open Field Test -  Qualitative and quantitative measure of general locomotor activity and willingness to explore in rodents, after a drug 
administration. 
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of affinity of salvinorin A with dopamine D2 receptors (Willmore-Fordham et al., 2007). 
Nevertheless, although high doses of salvinorin A produced a decrease in dopamine levels, low 
doses of salvinorin A seemed to produce an increase in dopamine levels. Unfortunately, the 
full mechanism of connections between k-opioid receptors, dopamine structures and 
salvinorin A are not totally understood (Braida et al., 2008; Listos et al., 2011).  
Some studies tested the hypothetical interaction between salvinorin A and the 
endocannabinoid system (Braida et al., 2008; Butelman et al., 2009). Rimonabant (a 
cannabinoid receptor antagonist) reverses rewarding effects of a low dose administration of 
salvinorin A, evidenced in place preference test, with rats and mice (Braida et al., 2009). 
However, in vivo studies revealed significantly different behavior patterns after administration 
of salvinorin A and cannabinoids, such as tetrahydrocannabinol. Mice treated with salvinorin A 
had less hypothermia and catalepsya than those treated with tetrahydrocannabinol. Salvinorin 
A also failed to substitute tetrahydrocannabinol, in mice (Walentiny et al., 2010). 
First studies about salvinorin A addictive properties concluded that it did not induce 
dependence. Nevertheless, behavioral studies in Wistar rats evidenced addictive effects. The 
rewarding effect of the compound was found after administration of low doses (0.1, 10 and 40 
µg/kg) (Braida et al., 2008).  
In opposite to other psychoactive drugs, such as synthetic amphetamine derivatives, 
which have critical severe adverse toxic effects, the consumption of salvinorin A does not 
appear to have relevant physiologic side effects. Mowry et al. (2003), in a study with Swiss-
Webster mice showed minimal changes in body temperature, sympathetic nervous system 
activity and worthless cardiac consequences, after administering 1600 µg/Kg of salvinorin A. 
Regarding histological modifications, no changes were observed in tissues from liver, spleen, 
kidney, bone marrow or brain. 
Notwithstanding, there are not currently many studies concerning toxic effects of 
salvinorin A. Some data predicted that it might be a reproductive toxicant in mammals 
(rabbits, rats and mice), but the information in this matter is scarce (Simpson et al., 2009). 
 
3.3.3 – Studies in humans 
 
The evaluation of endocrine effects, after salvinorin A inhalation, in a cohort of 10 
individuals, revealed high levels of prolactin (probably because salvinorin A lowers dopamine 
via KOR agonism) and cortisol in plasma. These results demonstrate the stimulation induced by 
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salvinorin A to the hypothalamic-pituitary-axis activity. Psychoactive effects, measured by the 
Positive and Negative Syndrome Scale (PANSS) and Psychotomimetics States Inventory (PSI), 
were very clear and, in accordance with effects of δ-9-tetrahydrocannabinol and ketamine 
(Ranganathan et al., 2012). 
In a survey with eight individuals (adults), the participants inhaled salvinorin A in 
crescent doses of 0.375-21 µg/Kg no changes in blood pressure, heart rate and tremors were 
observed. Anxiety rate during monitoring in human surveys was also low (MacLean et al., 
2013). 
In a recent case report, a 51 years woman who smoked 3-5 cigarettes of Salvia 
divinorum for 3-4 months, experienced vomits, nausea, diarrhea and abdominal discomfort, 
48h after quitting the drug. This case evidenced possible withdrawal syndromes of chronic use 
of Salvia divinorum which might became more and more frequent with the widespread use of 
this plant (Travis et al., 2012). 
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3.4 Therapeutic effects of salvinorin A 
 
3.4.1 – Ex vivo studies 
 
Aviello et al. (2011), performed some studies using a cell line of peritoneal 
macrophages collected from mice, showing that salvinorin A has an ultrapotent effect on 
inflammatory response, experimentally caused by intraperitoneal injection with 10% sterile 
thioglycollate medium. These findings might be useful to diminish acute inflammation, and 
were observed after lipopolysaccharide paw edema and inflammation-sustained pain, induced 
in imprinting control region. Usually, during an inflammatory response, nitric oxide levels are 
high, however after administration of salvinorin A, the levels of nitric oxide and relevant 
metabolites were much lower. In order to understand the extension of effects of salvinorin A 
on inflammatory response, it was compared with the effectiveness of dexamethasone. 
Salvinorin A proved to be more effective.  
 
3.4.2 – Studies in animal models 
 
Salvia divinorum was used by the Mazatec Indians for healing some gastrointestinal 
problems. It is attributed to Salvia divinorum infusions, curative properties in a disease called 
“panzon de barrego” (swollen abdomen) as well as for relieving diarrhea (Capasso et al., 2008; 
Fichna et al., 2009). It has also been attributed to salvinorin A the inhibition of enteric 
cholinergic excitatory transmission, thus inhibiting contractility in the isolated guinea pig 
ileum. In the presence of salvinorin A, the twitch response induced by electrical field 
stimulation, mediated by acetylcholine from myenteric nerves, remained unchanged (Capasso 
et al., 2006). Some studies, performed in mice, showed that salvinorin A reduced the intestinal 
transit, through inhibition of ilea smooth muscle hypercontractility, by binding to KOR. 
Salvinorin A inhibits colonic motility, through the inhibition of neurogenic active ion transport, 
in mouse colon (Fichna et al., 2011; Fichna et al., 2009). 
These findings might be relevant for the hypothetical importance of salvinorin A in the 
treatment of hypermotility of gastrointestinal motor function during endotoxemia, which 
occurs during gram-negative bacteria infections. Salvinorin A has the further advantage of 
preventing epithelial barrier dysfunction, as smooth muscle contractions of the colon decrease 
(Fichna et al., 2011; Fichna et al., 2009).  
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In a study in which chronic pain was induced in mice by formalin injection, salvinorin A 
has demonstrated to reduce mechanical allodynic effect and has elicited a reduction of spinal 
neuron hiperexcitability associated with chronic pain development. Salvinorin A has a positive 
effect in the treatment of inflammatory process and edema (Guida et al., 2012). However, it is 
important to recall that the potent analgesic effects of the kappa opioid receptors agonists is 
associated with many negative side effects like diuresis, sedation and psycothomimesis (John 
et al., 2006). 
Salvinorin A anxiolytic/antidepressant potential has been studied in rodents. It was 
demonstrated that salvinorin A reduced anxiety (shown in the elevated plus-maze test [8]) and 
depression (measured by forced swimming test, locomotor activity and tail suspension test[9]) 
by its interaction with kappa opioid receptors and endocannabinoid system (Braida et al., 
2009). More studies are needed to understand these biochemical interactions, since 
antidepressant effects may not be always the result of salvinorin A administration. In fact, few 
studies displayed depressive-like effects of salvinorin A depending on the administered dose 
(Braida et al., 2009; Carlezon et al., 2006).   
 
  
[8] Plus-Maze Test – This test uses a plus-shaped apparatus with two open and two enclosed arms, each with an open roof, and is based on the 
rodent’s aversion of open spaces. The raise of anxiety leads the mice to confining its movements to the enclosed spaces.   
[9] Tail Suspension Test – In this test, the rodent is suspended by the tail from a lever and the movements of the animal are recorded. It occurs 
immobility moments and agitation periods. Usually, antidepressants induce decreased duration of immobility.  
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3.5- Potential therapeutic interest of salvinorin A derivatives 
 
Towards obtaining better clinical results, many modifications and substitutions in the 
primary chemical structure of salvinorin A have been advanced. Positions C-1, C-2, C-4, C-17, C-
18 and the furan ring itself have been altered (Harding et al., 2006; Harding, Tidgewell, Byrd, et 
al., 2005; Munro et al., 2005; Vortherms & Roth, 2006) (Fig. 10). 
 
 
Fig. 10 - Salvinorin A chemical positions that have been submitted to modifications (blue colored) 
 
 
It has been demonstrated that the C-2 position of Salvinorin A is one of the important 
binding sites to kappa opioid receptors. In order to formulate new drugs, with clinical purposes 
and better tolerance and in vivo stability, some modifications in this carbon have been made. 
For example, the synthesis of C-2 analogs like methoxymethyl ether and ethoxymethyl ether 
exhibit higher binding affinity and potency than salvinorin A to kappa opioid receptors. The 
first one also displays longer duration of action (Beguin et al., 2006; Lee et al., 2010). N-
methylacetamide and 2-epi-isopropylamine derivatives, which provide increased stability and 
aqueous solubility are full agonists at KOR, having comparable strength to salvinorin A 
(Vortherms & Roth, 2006). Other synthetic analogues of salvinorin A, salvinorinyl-2-propionate 
and heptanoate derivative, revealed partial agonist activity at KOR’s. Nevertheless, either 
heptanoate or propionate derivatives have much lower KOR affinity than salvinorin A (Chavkin 
et al., 2004). It is important to report that the C-2 position can only be occupied by small (3-4 
carbons) lipophilic groups (Beguin et al., 2006; Chavkin et al., 2004; Lee et al., 2010). Lacking 
hydrophobic groups at such important binding position as C-2 (occurring the same at C-18) will 
result in a decreased affinity for kappa opioid receptors (Li et al., 2007). Given the fact that 
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halogen binding in biomolecular systems have gained wide acceptance, C-2 fluoro – , bromo- , 
cloro- and iodo- analogs of salvinorin A have been designed and evaluated about their 
affinities to µ-opioid receptors (MOR), δ-opioid receptors (DOR) and KOR. Some results have 
been observed: C-2-β isomer generally binds better than α isomer (with exception of iodinated 
analogs), and the affinity to the kappa opioid receptors increases with atomic mass (I > Br > Cl 
> F) (Lee et al., 2010). It is interesting to note that the decrease of affinity for kappa receptors 
caused by some of the changes in C-2 position (for example the introduction of an aromatic 
group), coincides with an increased affinity for µ-receptors (Harding et al. 2005; Tidgewell et 
al., 2006). 
Changes at C-4 position suggested that the methyl ester group is essential for kappa 
opioid receptors activity (Lee et al., 2006). Nevertheless, changes in C-4 position are better 
tolerated than changes in C-2 position, since the derivates do not suffer an affinity decrease so 
evident (Tidgewell et al., 2006). Meanwhile, C-18 replacements by dimethylamide derivatives, 
esters, amines and ethers diminishes the affinity for KOR as well as the reduction induced in 
the C-1 ketone to a hydroxyl or acetoxyl group. Modifications made at the furan ring 
(experimentally replaced by N-sulfonylpyrrole, triazole analogs or oxadiazole analogs) and C-8 
position led to a dramatic low level affinity for the KOR, at about ninetyfold less affinity and 
seventyfold less affinity, respectively. The obtained results, mainly enabled to realize that the 
methyl ester at C-4 and the furan ring at C-12 are fundamental for activity at KOR, while C-17 
lactone is not so important (Harding et al. 2005; Munro et al., 2005; Yang et al., 2009).  
Modifications and substitutions induced at the C-1 ketone of salvinorin A alter the 
agonist potential of the drug at the kappa opioid receptors. Therefore, analogues that have 
not the C-1 ketone, bind to opioid receptors in a different manner, producing an antagonist 
behavior, instead the typical agonist behavior (Holden et al., 2007). 
Besides the fact that oxadiazole analogues disturb the connection and affinity for the 
KOR, substitution of the furan ring with a 4-methyl-1,3,5-oxadiazoline ring was identified as 
the first neoclerodane diterpene with kappa antagonist activity alongside with salvidivin A 
(synthetically obtained by photo oxidation of salvinorin A) (Simpson et al., 2007).  
A careful and individual analysis to each target compounds of the molecular structure 
of salvinorin A, revealed the absence of any kind of bound with µ or δ opioid receptors. This 
result shows that salvinorin A will withstand considerable modification without losing its 
selectivity, since it will not establish any connection with other receptors besides KOR. The 
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affinity of the molecule might be decreased, but its selectivity will always be maintained 
(Munro et al., 2005). 
It has been attributed to the furan ring of salvinorin A its earlier mentioned toxicity in 
reproductive system. Even recognizing the importance of this structure to bind receptors, 
many attempts were performed to mimic the furan ring at its binding site (Lovell et al., 2012). 
Most of the replacements resulted in less affinity for the kappa opioid receptors. Yet, replacing 
the furan ring by a piperidine ring or a thiomorpholine ring led to the formation of a selective 
partial agonists at kappa opioid receptors (although having less potency than salvinorin A) 
(Simpson et al., 2009).  
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3.6 Methods for identification and quantification of Salvinorin A in different matrices 
 
3.6.1 – Detection of salvinorin A in plant material and commercial herbal 
products 
 
3.6.1.1 - Thin Layer Chromatography (TLC) 
 
TLC, although used for decades, continues to represent an important tool for the 
screening of compounds from vegetable origin, including drugs of abuse. Besides being a 
technique commonly adopted in the identification of methamphetamine, heroin and cocaine, 
it has already proven to be valid to separate alkaloids in Salvia divinorum leaves. TLC has 
shown ability to detect salvinorin A from extracted plant material and to easily distinguish 
Salvia divinorum from other Salvia species as well as from Cannabis sativa L. (Jermain & Evans, 
2009; Kennedy & Wiseman, 2010) (Table I).  
Kennedy and Wiseman (2010) developed a simple thin layer chromatography method 
combined with Desorption Electrospray Ionization-Mass Spectrometry (DESI-MS) that enabled 
salvinorin A detection in Salvia divinorum leaves. Besides the simplicity and inexpensive 
characteristics of TLC, this procedure combined the robustness of TLC with the sensitivity and 
specificity of mass spectrometry. Moreover, Siebert (2004) showed the high sensitivity for 
detecting salvinorins of TLC technique and, after preliminary experimentations, it was 
determined that salvinorin A can be detected in a 0.002% concentration solution. In a similar 
study, Jermain and Evans (2009) successfully extracted salvinorin A from commercial Salvia 
divinorum extracts (5X, 10X, 20X) using a chloroform:methanol  mixture. The detection of 
salvinorin A, B, C, D and G in S. divinorum was performed by TLC. By using this technique, it 
was also possible to differentiate Salvia divinorum from other 13 Salvia species (Table I).  
TLC has also been used for the localization of salvinorins in the plant. The method 
consisted in using chloroform swabs to extract salvinorins and evaluate the distribution 
pattern in leaf, steam, rachis, bract, calyx and corolla of mature plants. While the roots, 
internal stem tissue, cotyledons and corolla showed absence of salvinorins, the glandular 
trichomes of the abaxial, young leaves displayed the highest salvinorin content (Siebert, 2004) 
(Table I).   
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3.6.1.2- Liquid Chromatography 
 
Gruber (1999) successfully developed a high performance liquid chromatography 
method with UV detection for salvinorin A identification and quantification, in leaves and 
stems of Salvia divinorum. A reverse phase C-18 column was used as stationary phase and the 
mobile phase was acetonitrile:water (45:55) in isocratic elution. Salvinorin A eluted in 
approximately 8.0-8.1 minutes and levels of salvinorin A in leaves ranged from 0.89 to 3.70 
mg/g dry weight (Table I).  
Later, Medana et al. (2006) used liquid chromatography coupled with electrospray ion 
trap mass spectrometry (LC/ESI-IT-MS) to characterize Salvia divinorum leaves. This method 
waived the eventual high pH value that would lead to hydrolysis of the ester group. The ion 
fragmentation, separation and quantification of six different salvinorins (A-F) and three 
divinatorins (A-C) were described. Salvinorin A limit of detection using LC/MS was 3 ng/mL 
(Table I).  
Wolowich et al. (2006), in a similar study, investigated the content of five herbal 
products containing Salvia divinorum sold in the Internet or in several smart shops. The 
analysis was performed by high-performance liquid chromatography, but also by thin-layer 
chromatography and gas chromatography-mass spectroscopy, in order to detect other 
compounds, besides salvinorin A. Interesting results were obtained: salvinorin A 
concentrations were much lower than those claimed on the product label (1-16% of the 
claimed amount), and substances like vitamin E and caffeine were surprisingly found (Table I). 
Another study attempted to determine and quantify salvinorin A and salvinorin B in 
products circulating in Japan. The experimental protocol relied in high performance liquid 
chromatography with ultraviolet (UV) detection. The extraction solvent selected was 
acetonitrile because the extracts were cleaner than those obtained with methanol and 
acetone, and also presented high extraction efficiency (Tsujikawa et al., 2008) (Table I).  
 
3.6.1.3 - Gas Chromatography 
 
Barnes and Snow (2012) used GC-MS to identify and quantify Salvinorin A and other 
alkaloid molecules in Salvia divinorum plant. For that purpose, liquid-liquid extraction (namely 
with chloroform) and solid-phase micro extraction were performed in several tissues of Salvia 
divinorum plant (roots, stems and leaves), followed by analysis and identification in GC x GC-
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ToFMS (Gas Chromatography x Gas Chromatography – Time of Flight Mass Spectrometry). The 
methodology provided chromatographic separation of the closely related salvinorin analogs, 
being detected salvinorin A in stems and leaves, and salvinorin B and C only in leaves.  
Quantification was performed by using the characteristic fragments (m/z) of each molecule. 
Considering salvinorin A, the selected m/z ions were m/z: 94 (base peak), m/z: 166, m/z: 273, 
and m/z: 432 (molecular ion of salvinorin A) (Giroud et al., 2000) (Table 1).  
Jermain and Evans (2009)  analysed salvinorin A by GC/MS, performing the extraction 
from leaves with chloroform (when using a nonpolar solvent) and acetone (when using a polar 
solvent). Methanol was also tested, however a large amount of contamination 
chromatographic peaks was observed in the chromatogram, impairing the analysis. Combining 
an extraction of acetone or chloroform with GC/MS analysis, it was developed a fast procedure 
to evidence the presence of salvinorin A in plant material, which could be used for forensic 
purposes (Table 1).    
Willard et al. (2012a) analyzed Salvia divinorum and four other Salvia species by 
GC/MS. All species samples were submitted to an extraction with dichloromethane. Due to the 
presence of salvinorin A, visual assessment of the chromatograms allowed the distinction of 
Salvia divinorum from the other species. Still, total ion chromatograms were submitted to 
principal component analysis (PCA) to provide a more objective comparison. Visual assessment 
of PCA scores plot allowed a clearer identification of Salvia divinorum. Also multiple 
procedures as Euclidean distances, Student’s t test and hierarchical cluster analysis were 
performed (Willard et al., 2012a, 2012b). This methodology can be important to proofs to be 
presented in court (Table 1).  
 
3.6.1.4 - Molecular Methods 
 
Murphy and Bola (2013) managed to distinguish Salvia divinorum plant material from 
other plants, through the analysis of two different DNA sequences, that turned out to be 
specific of Salvia divinorum. The study of the sequence of the polymerase chain reaction of the 
ribulose bisphosphate carboxylase large subunit gene, enabled the differentiation between 
Salvia divinorum and other similar plants such as C. sativa and N. tabacum, whereas the study 
of DNA sequences adjacent to the chloroplast leucine transfer RNA gene, made possible to 
identify Salvia divinorum among other Salvia species.  
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Specific Salvia divinorum primers were designed on the sequence of the 5S-rRNA gene 
spacer region in order to develop Real-Time PCR detection strategies. This kind of procedures 
relies on continuous measurements of the increments in the fluorescence generated during 
the PCR. Real-Time PCR strategies present a broad dynamic range and low intra- and inter-
assay variability (Luciano et al., 2007). Using this DNA fingerprinting method, resulting PCR 
products and subsequent alignment of the isolated nucleotide sequences of Salvia divinorum 
(about 500 bp) and Salvia officinalis (about 300 bp) exhibited great diversities in the spacer 
region of the two species. Additionally, a PCR- restriction fragment polymorphism (PCR-RFLP) 
was applied using restriction enzymes (NdeI and TaqI). Based on this PCR-RFLP method, NdeI 
site that was absent in Salvia officinalis, was found in Salvia divinorum NTS region at 428-433 
bp and TaqI multiple sites found in Salvia officinalis (161-164, 170-173, and 217-220 bp) 
appeared in a unique site in Salvia divinorum (235-238 bp) (Bertea et al., 2006). 
Along with other molecular methods, DNA barcoding has also already been used to 
detect Salvia divinorum in some products distributed in the internet as incense, and advertised 
as not for human consumption (Ogata et al., 2013). 
 
3.6.2 – Detection of salvinorin A in human biological samples 
 
3.6.2.1 – Liquid Chromatography 
 
Analytical research of salvinorin A in body fluids has been object of study. A method 
using a solid-phase extraction technique coupled with liquid chromatography-electrospray 
ionization mass spectrometry gave promising results in blood and urine samples, with the limit 
of detection and limit of quantification standing respectively at 2.5 and 5.0 ng/mL 
(McDonough et al., 2008). This LC-MS methodology can be used in human biological fluid, 
however, it is important to sign that this method validation was conducted using certified 
drug-free urine instead of certified drug-free blood. Because half-life of salvinorin A is 
relatively short, and the dosage of the drug is very low, the blood sample would have to be 
collected almost immediately after exposure (Table 2). This implies that urine should be the 
biological sample indicated for legal purposes.  
Schmidt et al. (2005) performed analytical procedures that coupled negative ion liquid 
chromatography with mass spectrometry/atmospheric pressure chemical ionization in order to 
determine Salvia divinorum compounds in body fluids, mainly plasma, cerebrospinal fluid and 
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urine. This method, with a high sensitivity, allowed the identification of salvinorin B as a 
metabolite of salvinorin A in biological fluids. The drawback of this method was that the 
samples were ex vivo spiked with salvinorin A, rather than taken after the systemic 
administration of the compound, thus, it was an implementation method, performed by 
spiking human fluid samples with the compounds (Grundmann et al., 2007) (Table 2). 
 
3.6.2.2 – Gas Chromatography 
 
A method to quantify salvinorin A in urine, saliva and sweat, using gas 
chromatography/mass spectrometry was developed by Pichini et al. (2005). The analytes were 
extracted from biological matrices taken from two volunteers after smoking a fixed amount of 
plant material. Samples were extracted with chloroform:isopropanol (9:1, v/v) and the 
concentrations found ranged between 0.015 and 5 µg/mL in urine and saliva and between 0.01 
and 5 µg/patch in sweat. Recoveries ranged between 77.1 and 92.7% in the different biological 
matrices. The high drawback of this work was the number of samples: only two volunteers 
were involved in this study. Furthermore, it was not possible to have blood samples as the 
subjects refused blood collection after having smoked the plant leaves (Grundmann et al., 
2007) (Table 2). 
Besides the analysis of plant material, the already mentioned research of Barnes and 
Snow (2012), also applied GC x GC-ToFMS to analyze biological human samples, namely urine. 
The method was able to detect salvinorin A, but the most important conclusions were about 
the extraction procedure, which involved Solid-Phase Microextraction (SPME). SPME provided 
a better quantitative performance, with lower detection limit, thus being the most appropriate 
for physiological or clinical samples. Hence, Liquid-Liquid Extraction (LLE) represented a better 
alternative for researches on plant material, since it was more effective for higher 
concentrations (Table 2). 
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Table 1 - Published articles, about Salvinorin A detection and Salvia divinorum characterization using plant material or commercialized products with Salvia divinorum 
Analytical 
Procedurehttp://www.youtube.com/watch?v=9
z4Kft47Kbm 
Sample Extraction Techniques Analytical figures Main Results References 
GC X GC-ToFMS 
Stationary Phase: Two columns were used. The 
first one was a Phenomenex column 15m x 
0.25mm, with 0.25µm of inner diameter. The 
second column was an Agilent Technologies 
column 1.5m x 0.25mm, with 0.25µm of inner 
diameter 
Flow rate: 1 mL/min 
Salvia 
divinorum 
plant tissues 
(leaves, 
roots and 
stems) 
LLE: 
Solvents: Water and 
chloroform 
Calibration curve with linear 
range from 120 to 8000 
ng/g 
The highest quantity of salvinorin 
A was found in leaves. 
Nevertheless, only 60ng/g were 
obtained from the same tissue. 
Salvinorin B and salvinorin C were 
the most prevalent analogs of 
salvinorin A found 
Barnes et 
al., 2012 
TLC –DESI: 
2.5 x 7.5 cm sílica gel 60 F254 pre-coated TLC 
plates (250µm) 
Salvia 
divinorum 
leaves 
Extraction from the dry leaves 
in Acetone (1:5) 
Linear Range: 1 to 7 mg/mL 
R2 = 0.9998 
Development of a simple and 
robust method that successfully 
extracted salvinorin A 
Kennedy 
et al., 
2010 
TLC: 
Silica Gel Plates Whatman 250µm. 
Comercialize
d products 
with Salvia 
divinorum 
leaves 
Extraction from the dry leaves 
in Methanol: Chloroform (1:1) 
- 
It was able to detect salvinorin A, 
B, C, D and G and to differentiate 
Salvia divinorum from other 13 
Salvia species 
Jermain et 
al., 2008 
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TLC: 
Silica Gel Plates Whatman 250µm 
Salvia 
divinorm 
plant 
material 
Extraction was performed 
with 1 mL of chloroform for 
100 mg of each sample 
Lower limit of detection: 
0.002% 
It was able to clearly identify 
salvinorins A, B, C and D and to 
conclude that the neoclerodane 
diterpenes from Salvia divinorum 
are secreted as components of a 
complex resin that accumulates 
in peltate glandular trichomes 
Siebert, 
2003 
GC-MS: 
Stationary phase: J&W Scientific HP-5 (5% 
phenyl-methyl-siloxane) capillary column (15m x 
0.25m, with an inner diameter of 0.25µm) 
Carrier gas: helium 
Mass spectra collected in scan mode in the range 
of m/z 40-450 
Comercialize
d products 
with Salvia 
divinorum 
leaves 
Procedures of extraction 
tested: 
- Boiling chloroform for 10 
minutes; 
- Extraction with methanol at 
ambient temperature; 
- Extraction with chloroform 
at ambient temperature 
- 
The authors concluded that, 
when the analysis is performed in 
GC/MS, chloroform (when using a 
nonpolar solvent) and acetone 
(when using a polar solvent) are 
the best solvents to achieve 
extraction 
Jermain et 
al., 2008 
HPLC with UV detection (210nm) for quantitative 
analysis of salvinorin A 
LC-MS for quantitative analysis of salvinorin B 
Chromatographic separation performed with a 
Mightysil RP-18 column (2.0mm x 150mm, 5µm) 
Mobile phase: 0.05%formic acid in water and 
acetonitrile. Gradient analysis, with the following 
acetonitrile pecentages: 40%, 40-70%; 70-100% 
Comercialize
d products 
with Salvia 
divinorum 
leaves 
Extraction with acetonitrile 
(twice), followed by 
decoloration with graphite 
carbon powder 
 
Linear range for salvinorin 
A: 50-2000ng 
R2=0.993 
 
Linear range for salvinorin B: 
0-50ng 
R2=0.993 
 
The authors successfully 
identified and quantified 
salvinorin A and salvinorin B, 
from several different 
commercialized products 
Tsujikawa 
et al., 
2008 
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100%; 40%. 
HPLC/UV-MS: 
Chromatographic separation performed with  a 
Luna® Phenomenex column (2.0mm x 150mm, 
3µm) 
Gradient mobile phase composition: 80/20 to 
0/100 v/v water with 0.05% of formic 
acid/acetonitrile 
UV detector: 200-400nm 
 
GC-MS: 
Chromatographic separations ran in a Restek 
5Ms column (30 m x 0.25 mm) 
Mass Spectra collected in full-scan mode in the 
range m/z 100-650 
Salvia 
divinorum 
leaves 
Extraction was previously 
performed with 
acetonitrile/water (50:50) 
Limits of detection for 
LC/MS2: 
Salvinorin A: 3ng/mL; 
Salvinorin B: 7ng/mL; 
Salvinorin C: 2ng/mL; 
Salvinorin D: 9ng/mL. 
 
Limits of Detection for 
GC/MS: 
Salvinorin A: 40ng/mL; 
Salvinorin B: 51ng/mL; 
Salvinorin C: 46ng/mL; 
Salvinorin D: 36ng/mL; 
 
Limits of Detection for 
LC/UV (220+288 nm): 
Salvinorin A: 367ng/mL; 
Salvinorin B: 1144ng/mL; 
Salvinorin C: 221ng/mL; 
Salvinorin D: 128ng/mL 
The study allowed the study of 
nine different diterpenes. LC-MS 
revealed to be a particular useful 
technique for the analysis of the 
herbal products containing Salvia 
divinorum 
Medana 
et al., 
2006 
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Linear range: 10-5000ng/mL 
 
HPLC: 
Stationary phase: Zorbax 300 SB-C18 column 
(250m x 4.6mm, 5µm); 
Mobile phase: acetonitrile:water (45:55) 
Salvinorin A detection: UV 208nm 
Comercialize
d products 
with Salvia 
divinorum 
leaves 
Extraction performed with 
chloroform for 30 min 
Correlation Coefficient (r2): 
0.9998 
 
Salvinorin A concentrations were 
much lower than those claimed 
on the products labels. 
Substances such as vitamin E and 
caffeine were surprisingly found 
Wolowich 
et al., 
2006 
HPLC: 
Stationary phase: Zorbax 300 SB-C18 column 
(250m x 4.6mm, 5µm); 
Mobile phase: acetonitrile:water (45:55) 
Salvinorin A detection: UV 208nm 
Plant tissues 
(leaves and 
stems) of 
Salvia 
divinorum 
Extraction performed with 
chloroform for 30 min 
Correlation Coefficient (r2): 
0.9997 
 
The authors managed to develop 
one of the first procedures to 
successfully extract salvinorin A 
from Salvia divinorum plant 
material 
Gruber et 
al., 1999 
GC-MS: 
Stationary phase: DB-5MS column (30m x 
0.25mm x 0.25µm); 
Carrier Gas: Helium 1 mL/min 
 
Salvia 
divinorum 
leaves 
5 min extraction with 
dichloromethane 
Correlation coefficient (r2): 
0.9981 
It was possible to combine 
statistical procedures with 
GC/MS analysis, to improve the 
demonstration of differences 
between Salvia divinorum and 
other Salvia species 
Willard et 
al., 2012 
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GC-MS: 
Stationary phase: HP Ultra-2, 5% phenyl-methyl-
silicone capillary column (25m x 0.2mm x 
0.33µm); 
Carrier Gas: Helium 1.2 mL/min 
 
Commerciali
zed products 
with Salvia 
divinorum 
leaves 
Liquid-liquid extraction using 
a mixture of chloroform and 
isopropanol (9:1, v/v). After 
drying the plant material it 
was mixed with methanol and 
then dissolved in acetonitrile 
- 
This study represented one of the 
first successfully attempts to 
extract salvinorin A with GC/MS. 
It was possible to detect the 
major peaks at m/z: 94, m/z: 166, 
m/z: 273, and m/z: 432 
Giraud et 
al., 2000 
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Table 2 - Published articles, about Salvinorin A detection and Salvia divinorum characterization in biological matrices 
Analytical Procedure Sample Extraction Techniques Analytical figures Main Results References 
GC X GC-ToFMS 
Stationary Phase: Two columns were used. The 
first one was a Phenomenex column 15m x 0.25 
mm x 0.25µm. The second column was an Agilent 
Technologies column 1.5m x 0.250mm x 0.25µm 
Flow rate: 1 mL/min 
Human 
urine spiked 
with 
salvinorin A 
LLE: 
Solvents:  
Water and chloroform 
 
SPME: 
Polyacrilate fiber 85 µm 
 
Liquid-Liquid Extraction: 
LOD: 200 ng/mL. Linear 
range: 300-5000 ng/mL 
 
SPME: 
LOD: 4ng/mL.  
Linear range: 8-500 ng/mL 
SPME range proved to be more 
appropriate for clinical and 
physiological samples. LLE was 
found more effective for higher 
concentrations that may be 
found in plant material or 
products containing salvinorin A 
Barnes et al., 
2012 
LC-MS/APCI: 
Stationary phase: Phenomenex Polar-RP (150 
mm x 2.0 mm x 4µm) 
Isocratic analysis: 
Solvent A: 4mM Ammonium Acetate (50%); 
Solvent B: Acetonitrile (50%) 
Human 
Biological 
fluids (Urine, 
Plasma) 
Solid phase extraction: 
Cartridges were washed with 
10% methanol/water and 
dried with nitrogen. Analytes 
were eluted from cartridges 
with 75% dichloromethane in 
acetonitrile. Solvent was 
removed with nitrogen and 
samples ressuspended in 100 
µl of 75% acetonitrile/water 
LLOQ:2ng/mL 
Linear Range: from 2 to 
1000 ng/mL 
The method allowed the 
identification of salvinorin B as a 
metabolite of salvinorin A in 
biological fluids 
Schmidt et al., 
2005 
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LC-MS: 
Chromatographic separation performed with  a 
Luna® phenyl-hexyl column (Phenomenex, 
2.1mm x 100mm, 5µm) 
Mobile Phase: 0.1% formic acid and acetonitrile 
Gradient analysis, with the following acetonitrile 
percentages: 40%; 75%; 90% 
Human 
Urine 
Elution of the biological fluids 
with 25% of acetonitrile in 
dichloromethane 
Linear range for salvinorin 
A: 5.0-100 ng/mL 
R2=0.997; 
LOD: 2.5ng/mL; 
LOQ: 5.0ng/mL; 
 
The authors a method to 
successfully identify salvinorin A 
in human urine 
McDonough 
et al., 2008 
GC-MS: 
Stationary phase: 
Fused-silica capillary column (HP-5MS 30m x 
0.25µm) 
Carrier Gas: High purity helium (99%) at flow rate 
of 1 mL/min 
 
Biological 
Samples 
(blood, 
urine, saliva 
and sweat) 
All the samples were 
submitted to liquid-liquid 
extraction with chloroform / 
isopropanol (9:1) 
LOD for Plasma, Urine and 
Saliva: 0.005 µg/mL; 
LOQ for Plasma, Urine and 
Saliva: 0.015 µg/mL 
LOD for Sweat: 0.003µg/mL; 
LOQ for Sweat: 0.010 µg/mL 
Correlation Coefficients (r2): 
Plasma: 0.997; 
Urine: 0.999; 
Saliva; 0.996; 
Sweat: 0.999. 
This study was the first one to 
detect salvinorin A in urine and 
saliva samples, only 1.5h after 
consumption. A simple GC/MS 
procedure was able to identify 
salvinorin A in various biological 
matrices  
Pichini et al., 
2005 
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1- Objectives 
 
According to Favretto et al. (2013), some of the most important challenges of the 
moment in Forensic Toxicology are the new psychoactive substances, and the challenge to 
develop methodologies that can effectively detect and quantify them. Those remarks 
legitimize the present thesis, in which it will be studied one of the most prominent drugs, 
Salvia divinorum, easily available in smartshops and via internet. Besides the hallucinogenic 
effects induced by Salvia divinorum, its legal purchase in many countries, greatly justify the 
growing interest of the scientific community.   
In the present thesis, framed in the Master of Forensic Sciences, it was scrutinized the 
composition of 10 different samples of Salvia divinorum, that were, at the time of its purchase, 
legally sold on e-commerce and in “smart shops” in Portugal. 
The specific objectives of this work are to validate a protocol of extraction of salvinorin 
A and other related molecules from concentrated extracts of Salvia divinorum; test different 
solvents of extraction and choose the best one; determine the chemical composition of the 
products, evidencing the presence of the only hallucinogenic compound of the plant 
(salvinorin A); quantify salvinorin A and estimate the amounts of salvinorins B, C and D; 
confront the obtained results with previous similar researches on Salvia divinorum 
commercialized products and  evaluate the reliability and quality of the information that is 
provided to consumers in the packages of the products. 
Besides the specific objectives mentioned above, it was also intended to provide a 
literature review on the state of the art of Salvia divinorum, contribute to a better knowledge 
of the drug and to encourage a responsible attitude from both consumers and marketers, thus 
protecting society in general. 
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2- Materials and Methods 
 
2.1- Samples and Salvinorin A Standard 
 
Salvia divinorum extracts were purchased from September of 2012 until April 2013. 
Ten samples were purchased in four different “smart shops”: “Magic Mushroom” (Porto, 
Portugal), “Magic Mushroom” (Espinho, Portugal), “Cogumelo Mágico” (Aveiro, Portugal), 
“Euphoria” (Porto Portugal), and in 2 websites: http://azarius.pt/ and 
http://www.deliriumsmartshop.com (Fig.11, Fig.12). The samples are classified in “5x”, “10x”, 
“15x”, “20x”, “40x” or “60x” and the amounts of Salvia divinorum concentrated extracts were 
generally 1g. Many of the packages did not explain what this classification meant and if this is 
related to the salvinorin A contents. Only samples acquired from Azarius® guarantees through 
the above cited company’s website, that for example the “5x” extract has 12.5 mg of salvinorin 
A, while the “10x” extract contains 25 mg of salvinorin A. Packages from Euphoria “smart 
shop” have printed in the label that one gram of the “5x” extract equals five grams of Salvia 
divinorum leaves; one gram of the “10x” extract equals ten grams of Salvia divinorum leaves, 
and so on. Other information provided to customers is displayed in table 3, but, in most of the 
cases only scarce information was provided. 
 After the purchase, all the samples were kept in a humidity controlled environment, at 
room temperature (similar to the environment observed in “smart shops”). 
Salvinorin A standard was purchased from Sigma-Aldrich Chemie Gmbh (Munich, 
Germany), and allowed the identification and quantification of salvinorin A in the samples. 
Salvinorin A standard was kept at -20°C, in a humidity controlled environment, and protected 
from artificial light or sun light. 
 
 
2.2- Reagents 
 
Acetonitrile and acetone were purchased from Fisher Chemical®, having 99.99% and 
99.98% of purity respectively, according to GC assays. Chloroform was obtained from Fisher 
Scientific® and had 99.99% of purity, also determined by GC assay. Thymol, used as internal 
standard, was purchased from Sigma Aldrich®, and referred a purity ≥ 99.5%. All the other 
reagents were of the highest purity available but at least of analytical grade. 
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Fig. 11 - Packages of the acquired samples of concentrated extracts of Salvia 
divinorum 
Fig. 12 - Example of the usual presentation of bags containing Salvia divinorum 
extracts, and usual appearance of the extract 
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Table 3 - Information available in every packages of concentrated extracts 
 
Samples Responsible for selling Labeled Potency Batch Expiration Weight Additional information in packaging 
"Salvia divinorum 10x" - 
Magic Mushroom 
Magic Mushroom - Porto 10x 0b03 
Jun-13 /Apr-
13 
1g 
“Causes a state of unreal consciousness”; “Sensations similar to those 
obtained with marijuana”; “Use in a quite environment”; “Some people 
might experience slight headache, insomnia and bronchial irritation”; 
“Should be used in the presence of a sober person”; "Do not cause 
dependence"; "Not dangerous"; Historical Background 
"Salvia divinorum 
Extrato" - Euphoria 
Euphoria – Porto 5x 
21295
60 
Feb-14 1g 
Origin of the plant; "Forbidden to be purchased by minors"; “Provokes 
hallucinations, mind-body experience, travel to the past, becoming an 
object, presence in several places at once, and uncontrollable laughter”; 
“Do not smoke extracts stronger than 5x for the first time”; “Smoke in a 
bong or pipe”; "Do not cause dependence"; "Not dangerous" 
"Salvia divinorum 40x" - 
Magic Mushroom 
Magic Mushroom – Porto 40x 0d03 Jun-13 1g 
Historical Background; Traditional use by Mazatec indians; Preparation: 
”Boil about 200mL of water for a cup of tea and add the sage" 
"Sálvia divinorum  15x" - 
Cogumelo Mágico 
Cogumelo Mágico – Aveiro 15x ? Aug-14 0.5g 
How to use (“smoke in pipe or bong, or prepare a tea”); “Product 100% 
natural” 
"Sage Extract 10x" - 
Azarius.net 
Azarius® website 
http://azarius.pt/ 
10x ? ? 1g 
Origin of the plant; Effects (“hallucinations start in 10 minutes and last 
for 45 minutes”); Interactions (“Must be avoided simultaneous 
administration with alcohol, other drugs and monoamine oxidase 
inhibitors” 
"Salvia divinorum 20x" - 
Deliriumsmartshop.com 
"Delirium" website 
http://www.deliriumsmartshop.
com 
20x 0d03 Jun-13 1g 
Historical Background; Traditional use by Mazatec indians; Preparation: 
”Boil about 200mL of water for a cup of tea and add the sage" 
"Salvia divinorum 10x" - 
Magic Mushroom 
Magic Mushroom - Espinho 10x 0b03 Jun-13 1g 
“Causes a state of unreal consciousness”; “Sensations similar to those 
obtained with marijuana”; “Use in a quite environment”; “Some people 
might experience slight headache, insomnia and bronchial irritation”; 
“Should be used in the presence of a sober person”; "Do not cause 
dependence"; "Not dangerous"; Historical Background 
"Salvia divinorum 
Extrato" - Euphoria 
Euphoria – Porto 10x ? ? 1g 
Origin of the plant; "Forbidden to be purchased by minors"; “Provokes 
hallucinations, mind-body experience, travel to the past, becoming an 
object, presence in several places at once, and uncontrollable laughter”; 
“Do not smoke extracts stronger than 5x for the first time”; “Smoke in a 
bong or pipe”; "Do not cause dependence"; "Not dangerous"; “Smoke 
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salvia in a quiet, dark, environment”; “TV can destroy the experience, 
but appropriate music might be inspiring” 
"Salvia divinorum 
Extrato" - Euphoria 
Euphoria - Porto 40X L1840 Feb-14 1g 
Origin of the plant; "Forbidden to be purchased by minors"; “Provokes 
hallucinations, mind-body experience, travel to the past, becoming an 
object, presence in several places at once, and uncontrollable laughter”; 
“Do not smoke extracts stronger than 5x for the first time”; “Smoke in a 
bong or pipe”; "Do not cause dependence"; "Not dangerous"; “Smoke 
salvia in a quiet, dark, environment”; “TV can destroy the experience, 
but appropriate music might be inspiring” 
"Salvia divinorum 
Extrato" - Euphoria 
Euphoria - Porto 60X L1860 Feb-14 1g 
Origin of the plant; "Forbidden to be purchased by minors"; “Provokes 
hallucinations, mind-body experience, travel to the past, becoming an 
object, presence in several places at once, and uncontrollable laughter”; 
“Do not smoke extracts stronger than 5x for the first time”; “Smoke in a 
bong or pipe”; "Do not cause dependence"; "Not dangerous"; “Smoke 
salvia in a quiet, dark, environment”; “TV can destroy the experience, 
but appropriate music might be inspiring” 
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2.3- Experimental Conditions 
 
Gas-Chromatography analysis was achieved using a Varian CP-3800 gas chromatograph 
(USA) equipped with a Varian Saturn 4000 Ion Trap mass selective detector (USA) and a Saturn 
GC/MS workstation software version 6.8. Stationary phase consisted in a capillary column VF-
5ms (30m x 0.25mm x 0.25µm) from Varian (USA). Helium C-60 (Gasin, Portugal) at a constant 
flow rate of 1.0 mL/min, was used as mobile phase. Two microliters of each extract were 
injected using a split ratio 1:40 at 250 °C. The column oven temperature was maintained at 
100 °C for 1 minute and then raised to 300 °C at 15 °C/min and hold at 300 °C for 20 minutes 
totaling 34.3 minutes. Trap setpoint was at 180 °C, manifold setpoint was at 50 °C, and transfer 
line setpoint was at 280 °C. Electron energy was 70Ev. In order to avoid solvent overloading, 
ionization was maintained off during the first 4 minutes. Data were collected from m/z 40-
1000. The emission current was 30 µA and the maximum ionization time was 25000 µs. Mass 
spectra acquisition occurred between 4 and 34 minutes, after the injection of the samples.  
All determinations were performed in Full Scan Mode. For quantification purposes full 
scan chromatograms were reconstructed through the selection of qualifier ions for each 
molecule. The selected ions used for the quantitative measurements were: m/z 94, m/z 273 
and m/z 432 for salvinorin A; m/z 43, m/z 94, m/z 291, m/z 372 and m/z 390 for salvinorin B; 
m/z 94, m/z 313, m/z 372 and m/z 414 for salvinorin C; m/z 94, m/z 313, m/z 400 and m/z 432 
for salvinorin D.  
The identification of salvinorin A in samples was performed by comparison of retention 
time and mass spectrum of salvinorin A standard and salvinorin A in samples, under the same 
chromatographic conditions, and through the match probability obtained in SWG DRUG library 
of spectra. The remaining salvinorins in study (B, C and D) were identified comparing retention 
times and mass spectra of the peaks obtained upon the samples injection with previous 
published work and results obtained by Jermain and Evans (2009). 
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2.4- Extraction Procedure 
 
To determine the most effective solvent of salvinorin A from Salvia divinorum, three 
solvents with different polarities were tested (acetonitrile, acetone, and chloroform) (Table 4). 
The main objective was to extract the greatest amount of salvinorin A, but it was also 
important to extract salvinorin B, C, D and other related compounds. All the solvents 
extraction was tested in triplicate.  
 
 
Table 4 – Polarity indices of the three tested solvents 
 
 
 
 
 
 
2.4.1- Extraction with acetonitrile or acetone 
 
Samples were submitted to a process of extraction already performed by Tsujikawa et 
al. (2008), with some modifications, as for example the addiction of an internal standard to 
avoid misleading conclusions because of eventual losses during the extraction procedure. 
Thus, all the samples were grounded in a mortar into a thin powder. Then, 50 milligrams of 
each sample was transferred to a tube. In this tube, 2 mL of acetonitrile/acetone and 0.1 mL of 
the internal standard (thymol, 1mg/mL) were added, followed by one minute vortex shaking 
and five minutes ultrasonication. The mixture was centrifuged at 3000 rpm for three minutes, 
being the supernatant transferred into a second tube. To the first tube, it was added 2 mL 
more of acetonitrile or acetone, and it was again shaken, ultrasonicated, centrifuged and 
transferred to the second tube, being both extracts combined. The extractions were 
performed in triplicate for each sample (Fig. 13). 
 
 
 
 
Solvent Polarity Index 
Chloroform 4.1 
Acetone 5.1 
Acetonitrile 5.8 
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2.4.2- Extraction with chloroform 
 
 In order to perform the extraction with chloroform, 50 mg of the tested samples were 
submitted to extraction with 4 mL of chloroform. At this stage, 0.1 mL of the internal standard 
(Thymol 1 mg/mL) was added. The mixture was vortexed for 1 minute and ultrassonicated for 
5 minutes. Then, it was performed a filtration with a filter for organic solvents, thus separating 
the plant material from the concentrated solution (Fig. 14). 
 
 
 
Fig. 13 - Extraction Procedure Performed with Acetone or Acetonitrile 
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2.5- Concentrated Samples  
 
One extract of each sample was concentrated in order to identify different compounds 
that could be present in very low concentrations, as well as to evidence the presence of 
salvinorins C and D, that are presented in small amounts (very small peaks in the 
chromatograms). To achieve this, 2mL were taken from the solution obtained by the extraction 
procedures cited above, and were concentrated by evaporation of the solvent with slight 
nitrogen current (Fig. 15). 
 
 
 
 
Fig. 14 - Extraction Procedure Performed with Chloroform 
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Fig. 15 - Example of the Concentration of the Samples after Extraction (in this case with most polar 
solvents) 
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solvent (acetonitrile or acetone) 
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2.6- Method Validation 
 
According to Scientific Working Group for Forensic Toxicology (SWGTOX), the method 
validation may be defined as a process of conducting a series of experiments that estimate 
effectiveness and reliability of the analytical method, or modification of a previously validated 
analytical method. A method must be adequate for its purpose, and only validation may 
objectively evidence its reliability, by fulfilling a set of requirements, also proving its 
applicability. Although, establishing objectively that a method is capable of having a successful 
performance at the use for which it was developed, is not the only aim of validation. It is 
equally important to identify the limitations of the method under normal operating conditions 
(SWGTOX, 2013).  
In the field of Forensic Toxicology, validation is fundamental, in order to ensure the 
legitimacy of a method. According to Peters et al. (2007), the impact of unsubstantiated results 
might be felt in the scientific community, as well as in society. Regarding the scientific 
community, the unsubstantiated results may lead to undervalued or overvalued effects, false 
interpretations and unreliable conclusions. Relatively to forensic field, unsubstantiated results 
might not withstand the scrutiny of a court, where gathering objective evidence is primordial, 
or even worse, bring unfair consequences for the defendant, eventually contradicting the 
principle of in dubio pro reo.  
One of the most frequent concerns, regarding Salvia divinorum analytical studies, is 
the identification and quantification of its only hallucinogenic compound, salvinorin A. Taking 
into account the existence of few studies validated for the detection of salvinorin A, and the 
need to optimize the procedures, making them more effective and robust for forensic 
purposes, researchers continue to look for the best extraction procedure and the best 
analytical technique. As one of the objectives of this work was to validate a procedure that 
could identify and quantify mainly salvinorin A, but also salvinorins B, C and D, several solvents 
were tested and different extraction protocols were experimented.  
The presence of salvinorin A in samples was evidenced by comparing the mass 
spectrum of Salvinorin A in samples with those existing in SWGDrug and National Institute of 
Standards and Technology (NIST) 05 mass spectra libraries. It was also confirmed by using 
salvinorin A standard, which makes possible the quantification of this compound in samples. 
Regarding the identification of salvinorins B, C and D, standards were not available, therefore 
retention time and characteristic mass spectra from Jermain and Evans (2009) works were 
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taken into account. In order to quantify salvinorins B, C and D, the calibration curve obtained 
from the salvinorin A standard was conveniently adopted, being results presented as semi-
quantitative. 
To improve the quantitative analysis precision, an internal standard was added. 
Thymol (1mg/mL) was chosen since it is highly soluble in organic solvents, and is well 
separated from the other compounds present in samples. According to the Society of Forensic 
Toxicologists and the Toxicology Section of the American Academy of Forensic Sciences (SOFT-
AAFS), the introduction of an internal standard is recommended for all chromatographic assays 
(GC, HPLC). The internal standard must have physical and chemical properties similar to those 
of the analyte, and shall be added at one of the earliest stages of the procedure, if possible, in 
the extraction process (SOFT/AAFS, 2006). 
The extraction procedure and the analytical technique were submitted to validation 
criteria required by the European Medicines Agency (EMEA) (EMEA, 2011), Food and Drug 
Administration (FDA)  (FDA, 2001), and, according to the parameters that are commonly 
accepted as indispensable in quantitative and qualitative bioanalytical procedures such as: 
selectivity, linearity (model of calibration), limits of detection (LOD) and quantification (LOQ) 
and precision (repeatability).  
 
 
2.6.1- Linearity 
 
The construction of a calibration model is important to investigate the relationship 
between the concentration of the analyte in sample and the corresponding reply, which is, in 
this case, the area of the peak. According to most of the guidelines, 5 levels of concentration of 
the analyte is the minimum acceptable (Peters et al., 2007). Furthermore, the concentrations 
should cover the entire range of concentrations in the extracts to be analysed. The 
concentrations of the standard of salvinorin A that enabled the establishment of a calibration 
curve were: 0 µg/mL, 5 µg/mL, 10 µg/mL, 20 µg/mL, 50 µg/mL, 100 µg/mL, 200 µg/mL, 500 
µg/mL and 1000 µg/mL. It was added 40 µL of the internal standard in each solution.   
In order to quantify salvinorins B, C and D, and in the absence of standards of these 
compounds, the calibration curve obtained for salvinorin A was conveniently adapted.  Given 
the much lower values of the signals of these compounds, the quantity of salvinorin B was 
estimated with the calibration curve constructed with the following concentrations of 
Part II: Experimental 
 
 
 
 
62 
 
salvinorin A: 0 µg/mL, 5 µg/mL, 10 µg/mL, 20 µg/mL, 50 µg/mL, 100 µg/mL, 200 µg/mL, and for 
the quantification of salvinorins C and D the concentrations of 0 µg/mL, 5 µg/mL, 10 µg/mL, 20 
µg/mL, 50 µg/mL, 100 µg/mL of salvinorin A standard were used.  
The method linearity was evaluated by the square correlation coefficient obtained for 
each calibration curve (one for salvinorin A, one for salvinorin B and one for salvinorins C and 
D). SOFT-AAFS considers that, for most applications, 0.99 is considered an acceptable 
correlation coefficient. Only in certain circumstances, 0.98 might be considered a value 
minimally acceptable (SOFT/AAFS, 2006). 
 
 
2.6.2- Precision 
 
In order to evaluate the method‘s repeatability, it was determined intra-day and inter-
day precision. Mean, standard deviation and coefficient of variation were determined. 
According to Food and Drug Administration (FDA) (FDA, 2001) , the precision determined at 
any concentration level should be equal or less to 15% of the coefficient of variation. 
 
2.6.2.1- Intra-day precision 
 
In order to verify intra-day precision, it was performed 5 different aliquots of one same 
sample in the same day. The sample was held from a mixture of the different original samples. 
An amount of 50.0 mg from the referred mixture was extracted with 4 mL of acetonitrile (the 
concentration of each of the aliquots was 1.25 mg/mL), according to the established 
procedure. It was calculated the mean of the samples, as well as standard deviation and 
coefficient of variation. All injections were performed by the same operator and analyzed by 
the same apparatus.  
 
 
2.6.2.2- Inter-day precision 
 
Aiming to evaluate if the method was reproducible in different days, portions of 50.0 
mg of a mixture of different samples were submitted to analysis. Days 1, 3 and 4 were 
evaluated. On each day, five different amounts of 50.0 mg were extracted with 4 mL of 
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acetonitrile (the concentration of each of the new sample was 1.25 mg/mL), according to the 
established procedure. The means of salvinorins A, B, C and D of the three different days were 
compared, as well as the standard deviation and coefficient of variation. All extracts and 
injections were performed by the same operator and analyzed in the same apparatus.  
  
 
2.6.3- Sensitivity 
 
The limit of detection (LOD) expresses the minimum concentration of the analyte that 
can be detected, but not necessarily quantified, or the lowest concentration of the analyte in 
sample, that can reliably be differentiated from background noise (Peters et al., 2007). In order 
to determine the value of LOD, several methods might be implemented. One of the most 
common is the signal-to-noise ratio (S/N). When the determination is about the limit of 
detection, a S/N equal or greater than 3 is considered acceptable (SOFT/AAFS, 2006). 
The lower limit of quantification (LLOQ) represents the lowest amount of an analyte in 
a sample that can be quantitatively determined (Peters et al., 2007). So it can be determined 
with precision, one of the eligible methods, is also the signal-to-noise ratio. However in this 
case, it is usually required a S/N equal or greater than 10 (SOFT/AAFS, 2006).  
LOD and LLOQ concentrations were tested in quadruplicate, being the means, standard 
deviations and coefficients of variation taken into account. 
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3- Results and Discussion 
 
3.1- Selection of the solvent 
 
In order to select the best solvent among acetonitrile, acetone and chloroform, a 
mixture of several samples was prepared to test the extraction efficiency of the three solvents. 
The extraction of any of the solvents was performed in triplicate. 
 
Table 5 – Peak Areas of salvinorins resulting from extractions with different solvents 
Different 
Solvents 
SalA  SalB SalC SalD 
 
Mean 
Std. 
Deviation 
Mean 
Std. 
Deviation 
Mean 
Std. 
Deviation 
Mean 
Std. 
Deviation 
Acetone 
1.33E+07 6.20E+05 6.60E+06 3.47E+05 6.31E+05 5.24E+04 6.85E+04 4.41E+04 
Acetonitrile 
1.34E+07 1.42E+06 5.33E+06 7.67E+05 5.52E+05 7.07E+04 4.30E+04 2.09E+04 
Chloroform 1.21E+07 2.21E+06 5.96E+06 5.06E+06 5.72E+05 1.56E+05 ? ? 
 
All the solvents managed to extract salvinorins A, B and C, but the identification of 
salvinorin D was not possible using chloroform (Table 5).  
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Fig. 16 - Extractions of salvinorins A, B and C, with different solvents 
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Regarding the extraction procedure, Jermain and Evans (2009) referred that the best 
solvents to extract salvinorin A from Salvia divinorum samples were acetone or chloroform. 
However, this study lacked the comparison between the mentioned solvents with acetonitrile. 
Adopting the extraction procedure designed and validated by Tsujikawa et al. (2008) for both 
polar solvents tested, acetone and acetonitrile, the efficiency of extraction of salvinorin A was 
very similar, being acetonitrile slightly more effective, since the peak areas had higher values. 
Nevertheless, acetone revealed a homogenous extraction value between the assays, thus 
having a lower standard deviation and a higher precision (Fig. 16). As for the peaks shape, they 
were very similar, having a good resolution in both cases. With regard to extraction with 
chloroform, the mean of the peak areas of salvinorin A was much lower than the results 
obtained with acetonitrile. Nevertheless, once again, the resolution of the peaks was 
acceptable. Besides being the solvent with the lower extraction efficiency of salvinorin A, 
chloroform also had the disadvantage of not allowing the identification and quantification of 
salvinorin D in 2 of 3 trials. In addition, although the majority of crime laboratories usually 
accomplishes the extraction with chloroform (Jermain & Evans, 2009), the separation between 
the two phases is worst after centrifugation, than with other solvents. In fact, with chloroform, 
it is necessary to perform a filtration to remove the plant solid residue. The filtration process is 
fairly lengthy because of the large amount of plant material that eventually saturates the filter, 
implying its constant renewal. Admitting the importance of a fast recognition of the drug in 
forensic laboratories, this represents a relevant disadvantage.  
The extractions of salvinorins B, C and D were more efficiently performed using 
acetone as solvent. Nevertheless, only in the case of salvinorin B, the difference between the 
extraction performed with acetonitrile and acetone was substantially different. 
Towards the results obtained, the extraction with acetonitrile was the preferred. It was 
also considered results obtained from Tsujikawa et al. (2008)  evidencing that acetonitrile 
allowed a best rate of  extraction. 
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3.2- Method Validation 
 
3.2.1- Linearity 
 
Linearity studies were performed using salvinorin A standard ranging from 5 µg/mL to 
1000 µg/mL to quantitatively determine salvinorin A, whereas concentrations between 5 
µg/mL and 200 µg/mL were used to perform a semi-quantitative determination of salvinorin B. 
The selected range to semi-quantitative determine salvinorins C and D was 5-100 µg/mL (Table 
6).  
 
 
 
 
Table 6 - Values for Calibration Curve - Linearity 
Concentration 
(µg/mL) 
Ratio between peak areas  
(sal A/Int Std) 
0 0 
5 0.03 
10 0.11 
20 0.13 
50 0.37 
100 0.76 
200 1.36 
500 2.59 
1000 5.11 
 
 
 
 
The correlation coefficients obtained from the 3 calibration curves were above 0,99, 
being therefore acceptable according to SOFT/AAFS (2006) (Fig. 17-19). After the insurance of 
linearity of the defined models, equations of the lines made possible to determine the 
concentrations of the different studied salvinorins, in which “x” corresponds to the 
concentration of the analyte, and “y” is the value of the correspondent peak area ratio (sal A / 
Internal Standard) (Table 7). 
A 
B 
C; D 
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Table 7 - Calibration models for salvinorins A-D 
Compound(s) Equation of the line Range (µg/mL) R2 
Salvinorin A y= 0.05x + 0.1049 0-1000 0.9951 
Salvinorin B y= 0.0069x + 0.017 0-200 0.9958 
Salvinorins C and D y= 0.0076x + 0.0004 0-100 0.9962 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
y = 0,005x + 0,1049
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Fig. 19 - Calibration curve for salvinorins C and D 
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Fig. 18 - Calibration curve for salvinorin B 
Part II: Experimental 
 
 
 
 
69 
 
3.2.2- Precision 
 
The obtained results in intra-day and inter-day analysis revealed the precision of the 
adopted procedures of extraction and analysis of salvinorins A, B and C, since the intra-day 
(n=5) coefficient of variation was between 3.63% and 8.60%, and the inter-day coefficient 
ranged from  6.64% to 14.88% (n=3)  (Tables 8, 9). Although the intra-day coefficient of 
variation of salvinorin D revealed an adequate value of 9.22%, inter-day coefficient exceeded 
the 15% limit admitted by U S Food and Drug Administration (FDA, 2001) (Table 9). Extremely 
low concentrations of salvinorin D turned out to be a barrier to the semi-quantitative 
determination of the compound, revealing an inter-day precision of 18.22%. 
 
 
 
Table 8 - Intra-day Precision (n=5)  
Compound Mean (mg/g)   Standard Deviation(mg/g)   Coefficient of Variation (%) 
SalA 785.90 28.55 3.63 
SalB 332.54 28.59 8.60 
SalC 20.20 1.26 6.23 
SalD 4.18 0.39 9.22 
 
 
 
Table 9 - Inter-day Precision (n=3)   
Compound Mean (mg/g)   Standard Deviation (mg/g) Coefficient of Variation(%) 
SalA 758.22 50.32 6.64 
SalB 283.96 42.26 14.88 
SalC 18.70 2.58 13.82 
SalD 3.51 0.64 18.22 
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3.2.3- Sensitivity 
 
In the method validation of the present thesis, a signal-to-noise ratio of 3 was 
implemented to measure LOD. Salvinorin A concentration of 1.25 µg/mL was determined as 
LOD (Table 10; Fig. 20).  
Regarding LLOQ, a signal-to-noise ratio of 10 was studied. Concentration of 2.5 µg/mL 
was determined as LLOQ (Table 10; Fig. 20).  
 
Table 10 - LOD and LLOQ for salvinorin A 
Concentration Mean of Peak 
Areas 
Standard 
Deviation 
Coefficient of 
Variation 
S/N ratio 
1,25 µg/mL 7.35E+05 1.01E+05 13.73% 4 
2,5 µg/mL 1.20E+06 7.06E+04 5.90% 15 
 
  
Fig. 20 - Overlaped peaks for LOD (green line) and LLOQ (red line) concentrations 
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3.3- Salvinorins identification 
  
3.3.1- Salvinorin A detection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The selected ions used for the detection of salvinorin A were: m/z 94, m/z 273 and m/z 
432. In the chromatogram showed in figure 21, the retention time of the compound was 
18.099 minutes.  
 SWG DRUG library of spectra matched 80,4%, as the probability of being salvinorin A. 
Salvinorin A was the most abundant salvinorin in all samples.   
Fig. 21 Full scan reconstructed chromatogram of an acetonitrile sample extract using m/z 94, m/z 273, 
m/z 432, Salvinorin A characteristic m/z ions. 
Salvinorin A Retention 
Time: 18.099min 
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Salvinorin A standard revealed an identical mass spectrometry profile of the one 
present in samples.  The retention time was also similar: 18,169 min (Fig. 22).  
Fig. 22 – Full scan reconstructed chromatogram of salvinorin A standard using m/z 94, m/z 273, m/z 432 Salvinorin A characteristic m/z ions. 
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3.3.2 – Salvinorin B detection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The selected ions used for the detection of salvinorin B were: m/z 43, m/z 94, m/z 291 
m/z 372 and m/z 390. In the chromatogram above exhibited, the retention time of the 
compound was 17.001 minutes, which was similar in other studied samples. As evidenced in 
Fig.24, salvinorin B had the lowest retention time of all salvinorins, therefore eluting in first 
place.
Fig. 23 - Full scan reconstructed chromatogram of an acetonitrile sample extract using m/z 43, m/z 94, 
m/z 291, m/z 372, m/z 432, Salvinorin B characteristic m/z ions. 
Salvinorin B Retention 
Time: 17.001min 
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Scan Range: 1 - 2292 Time Range: 0.00 - 33.98 min. Date: 14-04-2013 23:44
5 10 15 20 25 30
minutes
0.0
0.5
1.0
1.5
MCounts A3.SMS 94.0 (Chan: 1) 
Salvinorin B (Retention 
Time: ≈ 16.995min) 
Salvinorin A (Retention 
Time: ≈ 18.092min) 
Salvinorin C (Retention 
Time: ≈ 18.750min) 
Salvinorin D (Retention 
Time: ≈ 18.940min 
Fig. 24 – Full scan chromatogram of a Salvia divinorum acetonitrile concentrated extract 
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3.3.3 – Salvinorin C detection  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The selected ions used for the detection of salvinorin C were: m/z 94, m/z 313 m/z 372 
and m/z 414. In the chromatogram above exhibited, the retention time of the compound was 
18.743 minutes.  
 
 
 
 
 
 
Fig. 25 - Full scan reconstructed chromatogram of an acetonitrile sample extract using m/z 94, m/z 313, 
m/z 372, m/z 414 Salvinorin C characteristic m/z ions. 
Salvinorin C Retention 
Time: 18.743min 
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3.3.4 – Salvinorin D detection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The selected ions used for the detection of salvinorin D were: m/z 94, m/z 313, m/z 
400 and m/z 432. In the chromatogram above exhibited, the retention time of the compound 
was 18.970 minutes. The identification of salvinorin D was very difficult because of the low 
concentration of the compound, and also because of the similar retention time of other 
compound, estimated to be β-sitosterol. The mass spectrum contemplates the characteristic 
m/z ions of β-sitosterol (such as m/z 414) (Huang et al., 2007). REPLIB library of spectra 
matched 46.2%, as the probability of being β-sitosterol. 
 
 
Fig. 26 - Full scan reconstructed chromatogram of an acetonitrile sample extract using m/z 94, m/z 313, 
m/z 400, m/z 432 Salvinorin D characteristic m/z ions. 
Salvinorin D Retention 
Time: 18.970 min 
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3.4- Quantification of salvinorins in the concentrated extracts 
 
3.4.1- Quantification of salvinorin A  
 
 
 
 
 
 
 
 
 
 
 
 
In most of the cases, the products that had higher labeled potencies had higher 
concentrations of salvinorin A (Table 9). However, there were some exceptions (Fig. 27; Table 
11). 
 
Table 11 - Salvinorin A concentration in different samples 
Samples Salvinorin A concentration (mg/g) 
Euphoria Porto "5x" 18.23 
Euphoria Porto "10x" 2.64 
Magic Mushroom Espinho"10x" 3.47 
Azarius.pt "10x" 33.94 
Magic Mushroom Porto "10x" 35.76 
Cogumelo Mágico Aveiro "15x" 20.92 
Deliriumsmartshop.com "20x" 44.48 
Magic Mushroom Porto "40x" 44.59 
Euphoria Porto "40x" 155.65 
Euphoria Porto "60x" 521.20 
Fig. 27 - Concentrations of salvinorin A in samples 
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3.4.2- Quantification of salvinorin B  
 
 
 
 
 
 
 
 
 
 
 
 
Salvinorin B, already identified as the most important metabolite of salvinorin A 
(McDonough et al., 2008; Schmidt et al., 2005), and the second most prevalent compound in 
Salvia divinorum samples, had, in the present work, concentrations directly proportional to 
salvinorin A concentrations.  
 
Table 12 - Salvinorin B Concentration in different samples 
Samples Salvinorin B concentration (mg/g) 
Euphoria Porto "5x" 2.38 
Euphoria Porto "10x" 1.59 
Magic Mushroom Espinho"10x" 2.43 
Azarius.pt "10x" 6.77 
Magic Mushroom Porto "10x" 5.91 
Cogumelo Mágico Aveiro "15x" 3.08 
Deliriumsmartshop.com "20x" 9.01 
Magic Mushroom Porto "40x" 6.38 
Euphoria Porto "40x" 25.04 
Euphoria Porto "60x" 117.86 
 
Fig. 28 - Concentration of salvinorin B in different samples 
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In order to study the relationship between the concentration of salvinorin A and 
salvinorin B, a model of linear correlation was studied (Fig. 29). The study tested the possibility 
of salvinorin B concentration be dependent on salvinorin A concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To evidence a statistically significant relation between the concentrations of both 
compounds, a test of hypothesis was also made. In this test, H0 represents the hypothesis of 
no linear correlation (H0: β1 =0). 
 
 
 
 
 
 
 
Fig. 29 - Linear Correlation Between Concentrations of Salvinorins A and B 
SalA Concentration 
mg/g 
SalB Concentration 
(mg/g) 
Part II: Experimental 
 
 
 
 
80 
 
Table 13 - SPSS output, on test of linear correlation between salvinorins A and B 
Coefficientsa 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
 1(Constant) -1.751 1.279  -1.369 .208 
SalA .225 .007 .996 30.584 .000 
a. Dependent Variable: SalB     
 
 
The SPSS 16.0 output provides a p-value (0.000) below the level of significance 
adopted (0.05) (Table 13). Therefore, it might be affirmed that the independent variable 
(salvinorin A) has statistically significant power to predict the dependent variable (salvinorin 
B), since it can be rejected the null hypothesis. The equation that traduces this relationship is: 
y= -1.751 + 0.225x. 
It was also possible to estimate the determination coefficient. According to the 
following SPSS 16.0 output, the adjusted R square possesses a value of 0.99 (Table 14). This 
means that, the independent variable average explains 99% of the variation of the dependent 
variable.  
 
 
Table 14 - SPSS output on prediction of salvinorin B concentration from salvinorin A concentration 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
.996a .992 .990 3.4895883 
               a. Predictors: (Constant), SalA  
 
 
 
 
 
 
p-value 
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3.4.3- Quantification of salvinorin C  
 
 
 
 
 
Salvinorin C concentration in samples was also directly proportional to salvinorin A 
concentration. Salvinorin C was the third most prevalent compound in the studied samples, 
after salvinorins A and B. 
 
Table 15 - Salvinorin C Concentrations in different Samples 
Samples Salvinorin C concentration (mg/g) 
Euphoria Porto "5x" 0.31 
Euphoria Porto "10x" 0.09 
Magic Mushroom Espinho"10x" 0.03 
Azarius.pt "10x" 0.66 
Magic Mushroom Porto "10x" 0.53 
Cogumelo Mágico Aveiro "15x" 0.08 
Deliriumsmartshop.com "20x" 0.33 
Magic Mushroom Porto "40x" 0.35 
Euphoria Porto "40x" 2.91 
Euphoria Porto "60x" 11.87 
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Fig. 30 - Salvinorin C concentrations in different samples 
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In order to study the relationship between the concentration of salvinorin A and 
salvinorin C, a model of linear correlation was studied, equal to the model applied to the study 
of the relationship between salvinorins A and B (Fig. 31). The study also tested the possibility 
of salvinorin C has its concentration dependent on salvinorin A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A test of hypothesis was made, to evidence a statistically significant relation between 
the concentrations of both of the compounds, similar to the previous one applied to the 
relationship between salvinorins A and B (H0: β1 =0). 
 
 
 
 
 
Fig. 31 - Linear Correlation Between Concentrations of salvinorins A and C 
SalA Concentration 
(mg/g) 
Sal C Concentration 
(mg/g) 
Part II: Experimental 
 
 
 
 
83 
 
Table 16 - Table 9 - SPSS output on test of linear correlation between Salvinorins A and C 
Coefficientsa 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
(Constant) -.319 .109 
 
-2.918 .019 
SalA .023 .001 .997 36.763 .000 
a. Dependent Variable: SalC     
 
 
The SPSS 16.0 output provides a p-value (0.000) below the level of significance 
adopted (0.05) (Table 16). Therefore, it might be affirmed that the independent variable 
(salvinorin A) has statistically significant power to predict the dependent variable (salvinorin C), 
since it can be rejected the null hypothesis. The equation that traduces this relationship is: y= -
0.319 + 0.023x. 
It was also possible to estimate the determination coefficient. According to the 
following SPSS 16.0 output, the adjusted R square possesses a value of 0.993 (Table 17). This 
means that, the independent variable average explains 99.3% of the variation of the 
dependent variable.  
 
 
 
Table 17 - SPSS output on Prediction of salvinorin A concentration over salvinorin C concentration 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
.997a .994 .993 .2983484 
a. Predictors: (Constant), SalA  
 
 
 
 
 
p-value 
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3.4.4- Quantification of salvinorin D  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Among all salvinorins detected, salvinorin D was the least representative. Most of the 
samples had very small concentrations of salvinorin D, and in one of the samples it was not 
possible to detect and quantify it (should be remembered that the determined LOD and LLOQ 
of salvinorin A standard were respectively 1.25µg/mL and 2.5 µg/mL) (Table 18). 
 
Table 18 - Salvinorin D Concentrations in different Samples 
Samples Salvinorin D concentration (mg/g) 
Euphoria Porto "5x" 0.04 
Euphoria Porto "10x" Not determined 
Magic Mushroom Espinho"10x" 0.01 
Azarius.pt "10x" 0.10 
Magic Mushroom Porto "10x" 0.12 
Cogumelo Mágico Aveiro "15x" 0.03 
Deliriumsmartshop.com "20x" 0.13 
Magic Mushroom Porto "40x" 0.12 
Euphoria Porto "40x" 0.05 
Euphoria Porto "60x" 0.32 
 
Fig. 32 - Salvinorin D Concentrations in different samples 
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3.5- Comparison with previous studies 
 
As long as we know, the literature presently reports two scientific studies concerning 
the identification and quantification of salvinorin A in concentrated extracts of Salvia 
divinorum. These works from Wolowich et al. (2006) and Tsujikawa et al. (2008) only 
contemplated samples with labeled potencies ranging from “1x” to “20x” and from “2x” to 
“25x”. Our study was the first to analyze commercialized products with labeled potencies as 
high as “40x” and “60x”.  
Although the labeled potencies of the purchased products in both mentioned studies 
are approximately in the same range, the results obtained were different. While Wolowich et 
al. (2006) presented a range concentration of salvinorin A between 0.126 – 0.951 mg/g, 
Tsujikawa et al. (2008) presented a range concentration between 4.1-38.9 (mg/g).  
In order to compare the range of concentrations with both mentioned published 
works, it was only taken into account the seven samples in which the labeled potency was 
between “5x” and “20x”. The obtained range is similar to the one presented by Tsujikawa et al. 
(2008): 2.6 mg/g and 44.5 mg/g, thus, quite different from the other study (Table 19). 
 
Table 19 - Range of Concentrations of Salvinorins A and B in different researchs about concentrated 
extracts of Salvia divinorum 
Study (Considering samples with labeled 
potency between “2X” and “25X”) 
Range of concentrations of 
Salvinorin A (mg/g) 
Range of concentration of 
Salvinorin B(mg/g) 
Wolowich et al. (2006) (“1X”-“20X”) 
(n=5) 
0.126 – 0.951  Not determined 
Tsujikawa et al. (2008) 
(“2X”-“25X”) (n=9) 
4.1 – 38.9  0.26 – 2.4  
Present Study 
(“5X”-“20X”) (n=10) 
2.6 – 44.5  1.59 – 9.01 
 
 
To confirm the similarity of the results obtained by Tsujikawa et al. with the results 
obtained in our study, it was determined the concentration per unit of labeled potency ((mg/g) 
/ "x"potency) of each sample (Table 20).   
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Table 20 - Concentration of salvinorin A per unit of labeled potency in all samples from Tsujikawa et al., 
2008 and samples from the present study 
 
 
 
 
Student's t-test for independent samples was applied to evaluate if there was 
statistically significant evidence to reject the hypothesis of equality between two groups of 
samples (G1 corresponding to the present study, and G2 corresponding to Tsujikawa et al. 
(2008)) (Table 21). 
 
 
 
Table 21 - SPSS output on Student’s t-test for independent samples 
Autor N Mean Std. Deviation Std. Error Mean 
G1 10 2.8539 2.47395 .78233 
G2 9 1.2762 .34917 .11639 
 
 
 
 
 
 
 
 
Samples (Present Study)  
Concentration per unit 
of labeled potency 
((mg/g)/"x" potency) 
Samples (Tsujikawa 
et al., 2008) 
Concentration per unit of 
labeled potency 
((mg/g)/"x" potency) - 
Tsujikawa et al. 
Euphoria Porto "5x" 3.65 2x 2.05 
Euphoria Porto "10x" 0.26 7x 0.94 
Magic Mushroom Espinho"10x" 0.35 10x (A) 1.17 
Azarius.pt "10x" 3.39 10x (B) 1.00 
Magic Mushroom Porto "10x" 3.58 10x (C) 1.27 
Cogumelo Mágico Aveiro "15x" 1.39 14x 1.11 
Deliriumsmartshop.com "20x" 2.22 20x 1.37 
Magic Mushroom Porto "40x" 1.11 20x 1.03 
Euphoria Porto "40x" 3.89 25x 1.56 
Euphoria Porto "60x" 8.69 - - 
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According to the outputs obtained in SPSS 16.0, for a 95% Confidence Interval of 
Difference, the value “0” is in the interval [-0.18269; 3.33802], therefore, the hypothesis (H0) 
of equality between the results obtained, cannot be ruled out (Table 22). 
As to salvinorin B, the values obtained by Tsujikawa et al., ranged from 0.26 to 2.4 
mg/g. The present study recorded concentrations of the same compound, in similar potency 
labeled products (5x-20x), between a minimum of 1.59 and a maximum of 9.01 mg/g. Since it 
was not possible to acquire the standard of salvinorin B, its concentration was estimated 
adapting the calibration curve of salvinorin A, which may have associated errors. 
  
 Levene’s Test for 
Equality of Variances t- test for Equality of Means 
F Sig. t df Sig (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval 
of Difference 
Lower Upper 
Valores Equal variances 
assumed 
 
Equal variances 
not assumed 
7.996 .012 
1.891 17 .076 1.57767 .83436 -.18269 3.33802 
1.995 9.398 .076 1.57767 .79094 -.20010 3.35543 
Table 22 - SPSS output on Student’s t-test for independent samples 
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3.6- Comparison between the real concentration of salvinorin A and the the salvinorin A 
labeled in the marketed package 
 
Most of the purchased samples did not provide information about the concentration 
of salvinorin A, only referring the “potency” of the products. Azarius® website was the only 
manufacturer that indicated salvinorin A content. The sample from Azarius® (“10X”) had, 
according to the company’s website, 25 mg of salvinorin A. After the analysis of the sample, it 
was estimated a concentration of 34 mg of salvinorin A. Therefore, in this case, the marketer 
sustained a concentration 26% under its real concentration (Table 23). This misleading 
information might eventually cause intoxications, overdoses or tolerance towards this drug. 
 
Table 23 - Comparison of the amount of salvinorin A publicized by Azarius, and the amount 
experimentally determined 
 
The other marketer indicating the contents in salvinorin A, was Euphoria®. However, in 
this case, the mass of salvinorin A was not objectively mentioned. Instead, the company 
ensures that 1 g of "Salvia divinorum 5x" corresponds to 5 g of Salvia divinorum leaves; 1 g of 
"Salvia divinorum 10x" corresponds to 10 g of Salvia divinorum leaves; 1 g of "Salvia divinorum 
40x" corresponds to 40 g of Salvia divinorum leaves; and 1 g of "Salvia divinorum 60x" 
corresponds to 60 g of Salvia divinorum leaves (Fig. 33). 
In accordance to Medana et al. (2006) studies, the amount of salvinorin A in leaves of 
Salvia divinorum originating from Sierra Mazatec is 0.76% (w/w), while the amount of 
salvinorin A in Salvia divinorum leaves originating from Hawaii is 0.78% (w/w). On the other 
hand, Kennedy and Wiseman (2010)  ensured the extraction of 0.80% (w/w) of salvinorin A 
from Salvia divinorum leaves. 
In order to clarify the reliability of information provided by Euphoria®, all samples, with 
the exception of the one from Azarius®, were submitted to comparison between the 
experimentally determined concentrations of salvinorin A and the concentrations presumably 
advertised by the manufacturers. The percentages of the difference of the expected results 
and the ones obtained experimentally were determined (Table 24). 
Concentration of salvinorin A in Azarius® 
sample (10X) – Obtained result after analysis 
Concentration of salvinorin A in Azarius® 
sample (10X) – According to company’s 
website 
34mg 25mg (-26%) 
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The majority of samples had a concentration much lower than the expected, including 
3 out of 4 samples from Euphoria® (less 95%-2567% of the advertised concentration). Only the 
highest labeled potency sample (“60X”) from Euphoria® had an experimentally observed 
concentration approximate to the expected one (8%-12% above the expected). 
 Besides the lack of information about salvinorin A concentration, several samples 
revealed insufficient information about other items as batches (not mentioned in 3 samples) 
and expiration date (not mentioned in 2 samples, and with two different expiration dates in 
one sample). Some samples provide scarce information about how to use the drug (only 
stating that must be smoked in a pipe or bong, and sometimes explaining that it must be used 
to produce an infusion). Surprisingly, the information most often exhibited in the packages 
were the expressions "Do not cause dependence" and "Not dangerous" (both mentioned in 6 
samples). 
Fig. 33 - Concentration of the extracts, according to Euphoria 
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Table 24 - Comparison of the amount of salvinorin A estimated  by Euphoria and the amounts 
determined by previous scientific works 
 
  
 
 
 
 
 
Samples 
Real 
concentration of 
salvinorin A per 
(mg/g) 
Expected 
concentration of 
salvinorin A (mg/g) 
(Salvia divinorum 
originated from Sierra 
Mazateca)   -  (Medana 
et al., 2006) 
Expected concentration 
of salvinorin A  (mg/g), 
(Salvia divinorum 
originated from Hawaii) 
(mg) - (Medana et al., 
2006) 
Expected concentration 
of salvinorin A  (mg/g) 
per package (Kennedy & 
Wiseman, 2010) 
Euphoria Porto "5x" 18  38 (+111%) 39 (+116%) 40 (+122%) 
Euphoria Porto "10x" 
3 
 
76 (+2433%) 78 (+2500%) 80 (2567%)  
Azarius.pt ”10X” 34 76 (+124%) 78 (+129%) 80 (+135%) 
Magic Mushroom Porto 
“10x” 
36 76 (+111%) 78 (+116%) 80 (+122%) 
Magic Mushroom 
Espinho “10x” 
3 76 (+2433%) 78 (+2500%) 80 (+2567%) 
Cogumelo Mágico 
Aveiro “15x” 
42 228 (+443%) 234 (+457%) 240 (+471%) 
Deliriumsmartshop.com 
“20x” 
44 152 (+245%) 156 (+254%) 160 (+264%) 
Magic Mushroom Porto 
“40x” 
45 304 (+576%) 312 (+594%) 320 (+611%) 
Euphoria Porto "40x" 156 304 (+95%) 312 (+100%) 320 (+105%) 
Euphoria Porto "60x" 521 456 (-12%) 468 (-10%) 480 (-8%) 
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3.7- Amount known to induce hallucinogenic effects, in each sample 
 
The companies that sell Salvia divinorum concentrated extracts are not very accurate 
about the amount that must be smoked. Marketers usually advice to smoke a "small amount" 
of the content of the purchased product, regardless the labeled potency of the extract.   
 According to Siebert (1994), 200 µg of salvinorin A are generally enough to obtain 
hallucinogenic effects.  
Given the concentration of each sample, it was estimated the amount of the 
concentrated extract that was needed to obtain the pretended effects (Table 25). 
 
Table 25 - Amount of Salvia known to induce hallucinogenic effects, per sample 
  
Samples Salvinorin A 
Concentration (mg/g) 
Amount of Salvia known to induce 
hallucinogenic effects (mg)  
Euphoria Porto "5x" 18.2 11.0 
Euphoria Porto "10x" 2.6 75.8 
Magic Mushroom Espinho"10x" 3.5 57.7 
Azarius.pt "10x" 33.9 5.9 
Magic Mushroom Porto "10x" 35.8 5.6 
Cogumelo Mágico Aveiro "15x" 20.9 9.6 
Deliriumsmartshop.com "20x" 44.5 4.5 
Magic Mushroom Porto "40x" 44.6 4.5 
Euphoria Porto "40x" 155.6 1.3 
Euphoria Porto "60x" 521.2 0.4 
0,0 10,0 20,0 30,0 40,0 50,0 60,0 70,0 80,0
Euphoria Porto "5x"
Euphoria Porto "10x"
Magic Mushroom Espinho"10x"
Azarius.pt "10x"
Magic Mushroom Porto "10x"
Cogumelo Mágico Aveiro "15x"
Deliriumsmartshop.com "20x"
Magic Mushroom Porto "40x"
Euphoria Porto "40x"
Euphoria Porto "60x"
11,0
75,8
57,7
5,9
5,6
9,6
4,5
4,5
1,3
0,4
Needed amount of Salvia to reach 
hallucinogenic effects (mg) 
Fig. 34 - Needed amount (mg) of Salvia concentrated extract to reach hallucinogenic effects 
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In the studied samples the amount known to induce hallucinogenic effects ranged 
from 0.4 mg to 75.8 mg (Fig. 34). These results reveal, in all analyzed samples, that the 
consumption of a very small amount of the extract is able to produce hallucinogenic effects. 
Since most of the consumers do not have this knowledge when buying Salvia divinorum 
extracts with the highest labeled potencies, they are consuming excessive amounts of the drug 
that might eventually be extremely dangerous.  
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3.8- Critical analysis of prices of the concentrated extracts 
 
In order to evaluate the prices of the purchased products, two different approaches 
were made: the determination of a relationship between the price of the products and their 
labeled potency, and the association between the price and the salvinorin A concentration in 
samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to the results presented in Fig 35, there is a relationship between 
commercial prices and the labeled potency (Fig.35). Nevertheless, since the concentration in 
salvinorin A is not always in accordance with the labeled potency, this relation between the 
price and salvinorin A concentration is not proportional (Fig.36).  
 
 
 
 
Fig. 35 - Relationship between price and labeled potency 
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In some cases, buying products with a concentration of 18 mg/g costs half of the price 
of a product with a concentration of approximately 3 mg/g. These results suggest that some 
commercialized products might not correspond to the expectations of the consumers. 
Fig. 36 - Relationship between price and salvinorin A concentration 
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4- Conclusion 
 
A methodology using GC/MS analysis was developed to determine four important 
salvinorins (A, B, C, D) in ten Salvia divinorum commercialized products. The method 
developed showed a correlation coefficient of linearity of 0.9951 for salvinorin A, an intra-day 
precision between 3.63% and 9.22% and an inter-day precision between 6.64% and 18.22%. 
The LOD was 1.25 µg/mL and the LLOQ was 2.5 µg/mL.   
The concentrations of salvinorin A in the studied samples are, in some cases, much 
higher than the needed to obtain hallucinogenic effects, implying a meticulous weighing of the 
amount to be consumed, which certainly will not be done by consumers.  Besides, the labeled 
potencies do not match the real concentrations of salvinorin A. These facts might lead to 
eventual intoxications, overdoses or tolerance towards this drug. 
In conclusion, concerns about the sale of Salvia divinorum products either it is being 
considered legal or illegal must be reinforced. The analysis of concentrated extracts of Salvia 
divinorum, from different marketers, allowed the identification of four salvinorins, salvinorin A 
being the most prevalent. The presence of this compound ensures the hallucinogenic 
properties stated by the sellers, but there are several unreliable data provided to consumers 
that might be worrying. Most of the time, there is no information on salvinorin A 
concentration, but when it is available, generally does not correspond to the true amount 
present in products. Besides, the labeled potency that is always present in packages not always 
corresponds to a direct proportional concentration of salvinorin A, as expected.  
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